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Abstract
Foot-and-Mouth Disease Virus (FMDV) induces rearrangements of host-
cell membranes to generate vesicles that are believed to provide platforms for 
formation of the viral replication complex. The cellular origin of these vesicles 
and the properties that make them favourable for replication are poorly 
understood. For some Picornaviruses these vesicles are thought to derive from 
membranes of the secretory pathway. In this thesis, I have investigated a role 
for membranes of the secretory pathway in FMDV infection. Key cellular 
proteins involved in regulating the flow of membranes through the secretory 
pathway between the ER and Golgi were inhibited using expression of 
dominant-negative (dn) proteins and small interfering RNA (siRNA) and the 
effect on FMDV infection determined. Inhibition of ER export using a drug (H89) 
or Sar1 (the GTPase required for COPII transport vesicle formation at ER exit 
sites) reduced FMDV infection. In contrast, stabilisation of COPII coats, or 
inhibition of Arf1 or Rab proteins, that are involved in the secretory pathway 
after the formation of COPII vesicles, had little or no inhibitory effect on 
infection. Interestingly inhibition of Arf1, Rab1 or Rab2 enhanced infection. In 
contrast, Arf1 reduced infection by bovine enterovirus which is inhibited by 
Brefeldin-A, and therefore likely to be dependent on Arf1 for replication. These 
results show that Sar1 and/or COPII vesicle formation is necessary for FMDV 
infection and that inhibiting the formation of COPI coats is in some way 
advantageous to FMDV infection.  These results suggest that FMDV targets 
COPII vesicles membranes before the COPII/COPI exchange and facilitates 
FMDV infection and that COPI components are not required.  
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RNAi   Ribonucleic acid interference 
Sar  Secretion associated ras-related 
SAT  South African territories 
SDS  Sodium dodecyl sulphate 
Sec  Secretory 
shRNA  Short-hairpin ribonucleic acid 
siRNA  Short interfering ribonucleic acid 
SNARE Soluble NSF attachment protein receptor  
TBC  Tre-2/Bub2/Cdcl2 domain 
TG  Thapsigargin 
TGN  Trans-Golgi network 
UTR  Untranslated region 
vRNA  Viral ribonucleic acid 
VTC  Vesicular-tubule clusters 
Wt  Wildtype 
Wb  Western blot 
g  Microgram 
l  Microlitre 
m  Micrometer 
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1 Chapter One: Introduction 
1.1  Foot-and-mouth disease virus 
Foot-and-mouth disease virus (FMDV) is the aetiological agent of a 
highly infectious disease (FMD) of cloven hoofed animals, including cattle, 
sheep, goats and pigs, and over 70 other species of wildlife.  The OIE (Office 
International des Epizooties) recognise FMDV as an A list disease of major 
socio-economic importance for the livestock industry, with outbreaks resulting in 
the implementation of drastic control measures to limit economic damage (OIE 
Animal health code 2010).   
FMDV exists as seven serotypes,  known as type  A, O, C, South African 
Territories (SAT) 1, SAT2 and SAT3 and Asia 1.  Types A and O are the most 
prevalent worldwide, whereas there have only been sporadic outbreaks of 
serotype C in South America, East Africa and Pakistan in recent years (OIE 
2008).   SAT-1, -2 and -3 are usually found in Africa and members of the Asia 1 
are usually restricted to Asia.  FMD is endemic in parts of Africa, Asia and 
South America, while North America, Australia and New Zealand are 
considered FMD free countries. The majority of Europe is also considered FMD 
free, including the UK, apart from periodic outbreaks mainly from the Middle 
East. 
FMDV infection is initiated through the upper respiratory tract or lungs, 
causing infection of the epithelium (Hyslop, 1965; Sellars, 1971) and viraemia.  
The incubation period can be as little as 2-3 days or longer (up to 2 weeks) 
(Garland, 1990).  Infection is characterised by several vesicular lesions on the 
coronary band of the hooves and the mucosa of the mouth including the tongue 
and palate.  The disease can vary in severity, from causing death in neonates to 
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the full recovery of adults mainly due to a neutralising antibody response from 
4-5 days peaking at 28 days (Sutmoller and McVicar, 1976).   
FMD can be spread via air borne transmission (Donaldson et al., 1987) 
as infected animals excrete large amounts of virus, especially pigs 
(Alexandersen and Donaldson, 2002).  In addition FMDV can survive for long 
periods of time at a neutral pH, in low temperatures and may potentially be 
protected by soil, however, at pH 6.5 and below the virus is destroyed.  Infection 
of cattle, sheep and buffalo, but not pigs, can result in a carrier state where 
virus can still be isolated from the oropharynx for up to 4-5 months (Sutmoller et 
al., 1968) 
FMD can be controlled by both slaughter and the restriction of animal 
movements of infected animals, as seen in the 2001 outbreak in the UK, or by 
vaccination.  Current diagnostic techniques include the detection of serum 
antibodies and virus antigen by ELISA, the growth of virus on primary cell 
culture and RT-PCR of the highly variable P1 region of the viral genome, which 
is responsible for serotype variation. 
The currently available vaccines are inactivated virus preparations in a 
semi-purified state. The VP1 protein (VP1 2 and 3) in the vaccine is the 
immunological component which confers an active immunity.  Vaccines can 
include one or more serotype, but the strain used to vaccinate the animal must 
be antigenically matched to the current circulating strain that is causing the 
outbreak, as there is little or no cross-protection between or within serotypes. 
There are however limitations to the use of vaccines in an outbreak due to a 
delay between vaccination and protection of up to 14 days, and immunity has 
only been reported to last for up to 12 months (Cox, 2000).  There is also a 
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reluctance to vaccinate in FMD free countries due to OIE imposing trade 
embargoes due to the seroconversion of vaccinated animals (OIE Animal 
Health Code).  Currently vaccination does not provide sterile immunity or 
prevent vaccinated animals from becoming re-infected, in addition clinical signs 
are masked and current serological tests are unable to distinguish between 
vaccinated and naturally infected animals.  Therefore vaccination is an 
unpopular choice for the control of outbreaks in disease free countries.   
1.2  The Picornaviruses 
Picornaviruses are small, non-enveloped RNA viruses that include a wide 
range of human and animal pathogens e.g. Poliovirus, Human Rhinoviruses, 
Hepatitis A virus, Swine vesicular disease virus and FMDV. The Picornaviridae 
family comprises of twelve genera (ICTV 2010) which are further divided into 
one or more virus species that may contain several serotypes.  The current 
taxonomic structure of the Picornavirus family is shown in figure 1.1 (Knowles 
N. J  2010, private communication).  FMDV is the prototype member of the 
genus Aphthovirus, which also includes Equine Rhinitis A virus (ERAV).  As 
previously mentioned (see section 1.1) FMDV consists of seven serotypes 
which are antigenically distinct from one another and consist of a number of 
subtypes, (Domingo et al., 2003; Lea et al., 1994). 
All Picornaviruses contain a positive-sense single-stranded RNA genome 
surrounded by a protein capsid.  For most picornaviruses, the capsid comprises 
of 60 copies each of four structural proteins VP1-VP4 whereas for others (e.g. 
parechoviruses) VP0 is not cleaved into VP2 and VP4.  The genomes are 
approximately 8kb long and share an organisational similarity to eukaryotic 
cellular mRNA.  Like cellular mRNA the viral genome consists of a single open 
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reading frame (ORF) followed by a 3’ untranslated region (UTR) and a poly (A) 
tail. However, the viral genome differs from cellular mRNA in that it possesses 
an extended 5’ UTR, and a 5’ cap structure (normally used to initiate cellular 
RNA translation) is absent from the 5’ terminus of the genome.  In its place is a 
short virus-encoded peptide VPg (also known as 3B), which is covalently 
attached to the 5’ end of the genomic RNA.  VPg is rapidly lost from the RNA 
inside the host cell, which exposes a free 5’ end.  The open reading frame 
within the genomic RNA encodes for a polyprotein, which is proteolytically 
cleaved during synthesis by viral encoded proteases to produce the viral 
proteins required for virion assembly and genome replication.   
None of the viral proteins are required to initiate the infectious cycle, thus 
picornavirus RNA is infectious when transfected into cells (Belsham and 
Bostock, 1988).  The viral capsid, serves to protect the genome and ensure its 
delivery into the cell cytoplasm where viral replication occurs.  The viral non 
structural proteins play an important role in genome replication.  The first phase 
of intracellular replication is translation of viral RNA to generate the viral 
proteins within the cell.  Picornaviruses shut down host-cell translation to allow 
the production of viral proteins to take precedence (see section 1.6.2). The 
IRES located in the 5’ UTR is the site from which the cap-independent initiation 
of viral protein synthesis occurs. 
 Viral RNA is synthesised by the RNA-dependant-RNA-polymerase 
(3Dpol); additional viral proteins are also required to initiate this process (see 
section 1.6.3).  VPg acts as a primer to initiate RNA synthesis within a 
membrane associated complex (replication complex [RC]) that contains a 
number of additional viral proteins (section 1.6.4).  Replication takes place on 
cell membranes after the initial period of translation.  A switch in function of the 
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viral RNA from translation to genome replication occurs.  This switch is required 
as  translation of the viral RNA is not compatible with the movement of RNA 
polymerase from the 3’ end to the 5’ terminus (Gamarnik and Andino, 1998). 
Replication occurs by the synthesis of negative-strands from the input positive-
strand templates. The negative strands are then used as a template to produce 
multiple positive-sense infectious RNA’s which may be used for production of 
more viral protein or the packaging into progeny virion particles.  
1.3  The FMDV virion 
The FMDV capsid is an icosahedral structure, ~25nm in diameter and 
composed of 60 copies of each of the structural proteins VP1-4. The capsid 
proteins self assemble from a monomeric protein precursor (one copy each of 
VP0, VP1 and VP3) which assemble to form intermediate pentamers (Abrams 
et al., 1995). Twelve pentamers assemble into an icosahedral capsid that 
encapsidates the vRNA (Grubman et al., 1985; Guttman and Baltimore, 1977) 
(see section 1.7).   Capsid proteins VP1-3 fold into a well characterised 8-
stranded β-barrel and form the outer capsid structure (Acharya et al., 1989) 
whereas VP4 is located inside the capsid with the vRNA.  The strands of the β-
barrels of VP1-3 are connected by loops which form on the outer surface of the 
capsid. One such loop (the GH loop of VP1) creates a major antigenic site and 
contains the Arg-Gly-Asp (RGD) motif required for integrin cell receptor 
attachment (Jackson et al., 2003). 
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Figure 1.1  Unrooted Neighbour-joining tree of the Picornaviridae based on a comparison of the P1 
capsid region. The 12 currently recognised genera are shown in italics.  
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The FMDV capsid is different from other picornavirus as it possesses 
channels at the five-fold axis which allow the entry of small molecules such as 
CsCl which results in the particle having a high buoyancy density compared to 
other picornaviruses (Acharya et al., 1989; Jackson et al., 2003).  In addition 
VP1 and VP2 are significantly smaller in FMDV which results in a thinner 
protein shell, creating a smooth outer surface that lacks canyons or pits (Belnap 
et al., 2000; Hogle et al., 1985; Kolatkar et al., 1999; Luo et al., 1987; 
Muckelbauer et al., 1995; Rossmann et al., 1985; Xiao et al., 2001).  The capsid 
dissociates at a low pH (below 6.5) into 12s pentamers due to protonation of His 
residues at the pentamer/pentamer interfaces (Curry et al., 1995; Ellard et al., 
1999).  
1.4  FMDV genome organisation 
1.4.1 The 5’ UTR 
The 5’ UTR is required for both the initiation of viral protein synthesis and 
viral RNA replication.  The FMDV 5’ UTR (1300nt) (Forss et al., 1984) is longer 
than the majority of other picornaviruses  and  has five distinct regions including 
the S-fragment, a poly (C) tract, pseudoknots, a cis-acting replication element 
(cre) and an internal ribosome entry site (IRES) (see Figure 1.2) 
1.4.2 S-fragment
At the 5’ end of the 5’ UTR of FMDV RNA is a 360 nucleotide sequence 
termed the S-fragment that has been predicted to form a hairpin loop structure 
(Escarmis et al., 1992). This structure is believed to protect the genome from 
exonuclease digestion following the removal of VPg (Grubman and Bachrach, 
1979).  A similar structure is located at the 5’ end of the poliovirus (PV) genomic 
RNA (a cloverleaf structure of 80 nt) which has been reported to have a 
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significant effect on the viral RNA stability by protecting the termini of the viral 
RNA from degradation (Murray et al., 2001).  The PV cloverleaf is thought to 
interact with both cellular and viral proteins (Parsley et al., 1997) and is required 
for viral genome replication.  The cloverleaf is also thought to play a role in the 
switch from viral protein synthesis to genome replication (Gamarnik and Andino, 
1998) and for circularisation of the viral RNA during replication  (Herold and 
Andino, 2001).  Several studies have shown that cellular Poly (C) Binding 
Protein (PCBP) can, along with other viral and cellular proteins bind the 5’ 
cloverleaf structure of PV (Gamarnik and Andino, 1997). Recent, evidence 
indicates that PCBP could play a role in bridging the 5’ and 3’ ends of the 
poliovirus genome (Barton et al., 2001; Herold and Andino, 2001).  Although the 
function of the S-fragment remains largely unknown it is possible it may play a 
similar role to the PV cloverleaf in FMDV RNA replication. 
1.4.3 Poly (C) Tract and Pseudoknots  
Located at the 3’ side of the S-fragment within the FMDV 5’ UTR is a long 
stretch of C nucleotides (90%), termed the poly (C) tract. The poly C tract varies 
considerably in length between strains of FMDV, ranging from 80nt-120nt. 
Laboratory strains appear to contain shorter poly(C) tracts than field viruses, 
and viruses with fewer than 6 C nucleotides are infectious in cell culture (Harris 
and Brown, 1977).  Retention of the poly (C) tract within the viral RNA is under 
strong selection pressure as demonstrated by Rieder et al (1993); they 
produced recombinant FMDV containing 6 C residues.  Passage of this virus in 
cell culture resulted in selection of viruses with poly C tracts up-to 80nt in length 
thought to be due to recombination events. In comparison, recombinant viruses 
with just two C residues in the poly (C) tract did not alter in length.  The shorter 
poly C tract still produced viable virus but grew at a reduced titre when 
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compared to the recombinants with longer poly C tracts, however this virus 
displayed virulence in mice models equal to that of wild-type virus.  This 
suggested that the poly C tract does not have a role in virulence, but maybe 
necessary for the virus to grow to high titres (Rieder et al., 1993).   In addition, it 
is possible the FMDV poly (C) tract could be involved in circularisation of the 
genome by interacting with PCBP. 
On the 3’ side of the poly (C) tract, before the IRES in FMDV RNA, is a 
stretch of 250nts that are predicted to contain multiple pseudoknots.  The 
function of these pseudoknots is unknown, but they may work in conjunction 
with the poly C tract. 
1.4.4 Cis-acting replication element (cre)
Recent studies have shown that a short sequence within the genome, 
known as the cis-acting replication element, or cre, is vital for viral RNA 
replication.  A cre was first discovered in the P1-coding sequence of  Human 
Rhinovirus (HRV-14) and was shown to be essential for vRNA replication 
(McKnight and Lemon, 1996). Further study showed that the cre is a stem-loop 
structure containing an AAACA motif in the loop region.  Similar cre structures 
have since been identified in several other picornaviruses, including FMDV 
(Gerber et al., 2001; Goodfellow et al., 2000; Lobert et al., 1999; Mason et al., 
2002). The cre was found to be position independent and is located at different 
positions along the genome of different Picornaviruses.  FMDV contains a cre in 
the 5’ UTR upstream of the IRES (Mason et al., 2002) whereas in other 
picornaviruses it can be found in the protein coding region of the genome.    
Alteration of the stem loop AAACA motif in PV has been found to inhibit 
genome replication, but did not seem to have an effect on translation of the 
RNA (Mason et al., 2002).   
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The cre has been shown to act as a template to allow the viral RNA 
polymerase to uridylylate the VPg in vitro (Paul et al., 2000) producing a 
VPgpUpU.  The uridylylation of VPg is an essential step in replication, as the 
VPgpUpU acts as a primer to initiate viral replication  (Nayak et al., 2005; Nayak 
et al., 2006).    It has been suggested that negative strand synthesis is initiated 
with the uridylylation of the VPg at the 3’poly (A) tail in vRNA and positive strand 
synthesis is initiated by VPgpUpU synthesised on the cre hairpin (Morasco et 
al., 2003). However, it has also been suggested that VPgpUpU and the 3D 
polymerase (3Dpol) are translocated from the cre templates to the 3’ terminus 
of negative- and positive-strand RNA templates to prime the initiation of RNA 
synthesis (Goodfellow et al., 2003b; Lyons et al., 2001; Murray and Barton, 
2003; van Ooij et al., 2006). 
1.4.5 Internal Ribosome Entry Site (IRES) 
A sequence present at the 3’ end of the FMDV 5’ UTR is known as the IRES 
and is responsible for initiating viral protein synthesis (Belsham et al., 1990; 
Martinez-Salas et al., 1993) (see section 1.6.2).  The absence of a 7-methyl-G 
cap at the 5’ end of the viral genome prevents normal cap-dependant 
translation from occurring. To overcome this, translation is initiated at the IRES, 
which involves the direct recruitment of the translational machinery (Belsham 
and Brangwyn, 1990; Kuhn et al., 1990). The advantage of this process is that 
IRES dependent translation initiation can overcome stressful conditions that 
would otherwise inhibit cap-dependent translation initiation (Hellen and Sarnow, 
2001). The FMDV IRES is a highly ordered region of secondary structure 
consisting of about 460nt, and is organised into five structural domains.  The 
IRES of both aphthoviruses and cardioviruses share a common secondary  
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Figure 1.2 FMDV 5’ untranslated region  
The 5’ UTR of FMDV contains the S-fragment, ploy(C) tract , pseudoknots (PKs), cre with 
conserved loop labelled, IRES domains 2, 3, 4 and 5 and poly-pyrimidine tract leading to two 
stop codons (Mason et al., 2003) 
 
.   
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structure and are classified as a type II IRES (Pilipenko et al., 1989) (see Figure 
1.2).  FMDV translation is aided by a number of cellular trans-acting factors 
binding to the IRES, such as the polypyrimidine tract-binding protein (PTB) and 
the proliferation associated factor ITAF45, for the formation of a 48s complex in
vitro (Pilipenko et al., 2000).  The main binding site for PTB is near the 5’ end of 
the IRES which also interacts with the 3’ sequence (Luz and Beck, 1991). The 
FMDV IRES seems to form a modular organisation in which the different 
domains possess a distinct function but do not act independently. 
1.5  FMDV polyprotein 
The viral proteins are synthesised as a single polyprotein.  The 
polyprotein is co-translationally cleaved during viral protein synthesis by viral 
encoded proteases to produce a number of precursors and mature proteins 
which have important functions in virus replication.  In total, 15 different mature 
proteins including two forms of the leader (L) protein, and three different 
versions of VPg are produced (see Figure 1.3).   
1.5.1 Leader Protease 
 Two conserved AUG codons (84nt apart) are present within the viral 
genome (Sangar et al., 1987).  Both codons are preceded by polypyrimidine 
tracts, which is a common characteristic of the 3’ end of picornavirus IRES 
(Meerovitch et al., 1993), and both are used as initiation sites.  Therefore the 
FMDV genome encodes two separate forms of the Leader (L) protein, Lab and 
Lb that vary only in their N-termini.   The L protein (Hinton et al., 2002) is a 
papain-like cysteine protease.  Both forms of the FMDV L protein cleave the 
L/P1 junction resulting in its detachment  (Medina et al., 1993).  FMDV Lab and 
Lb are also known to cleave the eIF4G translation initiation factors (Belsham et 
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al., 2000) and thereby inhibit cap-dependant translation; consequently there is a 
promotion of viral protein synthesis and major loss of host cell protein synthesis.  
One advantage to inhibiting host cell protein synthesis is the reduced ability of 
the cell to mount an antiviral response such as the interferon response 
(Chinsangaram et al., 1999).  
1.5.2 The Capsid Precursor P1-2A 
 The removal of the L protease from the N-terminus of the polyprotein 
exposes residues on the N-terminus of VP4, which are recognised by the 
cellular myristylation machinery.  Myristylation is necessary for capsid assembly 
and is thought to play a key role in vRNA membrane penetration during cell-
entry (Abrams et al., 1995; Marc et al., 1991).  The capsid proteins are initially 
separated from the non-structural proteins by ‘cleavage’ after the 2A protein.  
The FMDV 2A protein itself does not possess any protease activity, ‘cleavage’ 
occurs as a co-translation event.  It is believed that 2A functions by preventing 
the synthesis of a peptide bond at the 2A/2B junction (Donnelly et al., 2001), 
releasing the P1 precursor from the polyprotein. In contrast, PV 2A protein 
possesses its own protease activity, and is known to cleave host cell translation 
initiation factors including EIF4G (Lloyd et al., 2006).  The P1-2A precursor is 
then processed by viral protease 3C into 1AB (VP0), 1C (VP3) and 1D (VP1).  
The cleavage of VP0 to VP4 and VP2 occurs when the RNA genome becomes 
encapsidated.  
1.5.3 P2 proteins 
 The other P2 proteins are 2B and 2C and are released from the P3 
proteins as the precursor 2BC by the action of 3C.  In FMDV infected cells, the 
3C protease rapidly cleaves the 2BC precursor to produce 2B and 2C.  Studies 
have identified that 2B contains hydrophobic regions (van Kuppeveld et al., 
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1996) and 2B has been observed to co-localise with ER membranes (Moffat et 
al., 2005). However the role of 2B in replication has not been determined. For 
PV and Coxsackievirus, 2B is known to form dimers and tetramers which are 
thought to result in the formation of viroporins.  Viroporins are transmembrane 
proteins that form pores and alter membrane permeability to ions (Sandoval and 
Carrasco, 1997).  For Coxsackievirus B3, 2B is reported to decrease 
intracellular Ca2+ signalling between cellular organelles and cause an 
imbalance in Ca2+ levels resulting in the suppression of the cells apoptotic 
response (Campanella et al., 2004).   
The 2C protein is one of the most conserved in picornaviruses and all 2C 
proteins are predicted to contain a helicase binding motif (Baltera and Tershak, 
1989; Klein et al., 2000; Pfister and Wimmer, 1999) which suggests RNA 
helicase activity. A recent report has demonstrated that FMDV 2C possesses 
ATPase and RNA binding activity (Sweeney et al., 2010).   An amphipathic helix 
present in the N-terminus of the FMDV 2C protein could provide a membrane 
anchor, as has been shown for other picornaviruses (Echeverri et al., 1998; 
Echeverri and Dasgupta, 1995; Kusov et al., 1998; Murray et al., 2009). The 2C 
of other picornaviruses also bind membranes and have been reported to induce 
membrane rearrangements and formation of the viral replication complex (RC) 
(Bienz et al., 1990; Tesar et al., 1989).  It has also been reported that 
picornavirus 2C proteins determine the viral RNAs sensitivity to the replication 
inhibitor guanidine, although different strains of FMDV display varying 
sensitivities to this inhibitor (Saunders and King, 1982).  PV 2C is thought to 
bind to the 3’ end of negative strand RNA intermediates and is crucial for vRNA 
replication (Goodfellow et al., 2003a). Recently, a direct interaction between PV 
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2C and the capsid protein VP3 suggest 2C plays a role in the formation of PV 
particles and vRNA encapsidation (Liu et al., 2010). 
Recent studies carried out on 2BC protein activity suggest that FMDV 
2BC binds to membranes and is able to block the secretory pathway within 
infected cells, preventing endoplasmic-reticulum-to-Golgi transport (Moffat et 
al., 2005).  Further investigation revealed that the FMDV block in secretion is 
dependent on both components (2B and 2C), with 2C determining the site of the 
block (Moffat et al., 2007).   
1.5.4 P3 Proteins 
In FMDV the P3 region consists of the 3A protein, three tandem copies of 
3B, the 3C protease and the 3D RNA-independent RNA-polymerase.  The 
FMDV P3 precursor is also processed by 3C protease.  The 3A protein is 
believed to provide an anchor for attachment to cell membranes at the 
localisation of RNA replication and is thought to deliver 3B to the RNA 
replication sites as 3ABBB in the case of FMDV (Belsham, 2005). FMDV 3A 
also localises to and binds membranes in infected cells and is thought to form 
part of the replication complex. PV 3A blocks protein secretion, however there is 
no evidence FMDV 3A blocks membrane traffic or plays a direct role in 
membrane rearrangements (Moffat et al., 2005).  3B is uridylylated and serves 
as a primer for synthesis of both positive and negative sense RNA (see section 
1.4.4). Recently, it has been shown that neither mutation nor deletion of any 
one of FMDV’s 3B proteins affects virus replication, or the virus’s ability to infect 
cattle, suggesting the three 3B proteins of FMDV are functionally 
interchangeable (Pacheco et al., 2010). 
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1.5.4.1 3C protease 
In FMDV the 3C protease is responsible for the majority of the 
polyprotein processing. The FMDV 3C functions alone, unlike that of PV which 
requires the precursor 3CD protease for efficient processing activity of the 
capsid (Ypma-Wong et al., 1988). The 3C protein is a trypsin-like serine 
protease (Grubman et al., 1995) and not only cleaves the viral polyprotein but 
also various cellular proteins.  It has been shown that  H3 histone (Falk et al., 
1990), and the translation initiation factors eIF4A and eIF4G1 are cleaved in 
cells infected with FMDV by 3C (Belsham et al., 2000).  By cleaving eIF4G1, 
FMDV 3C creates a form of protein that supports IRES function resulting in 
efficient viral protein synthesis (Belsham et al., 2000).  
Nayak et al (Nayak et al., 2006) demonstrated the uridylylation of FMDV 
VPg could be achieved in vitro with only VPg (3B), 3Dpol, 3C and an RNA 
template containing the cre, and there was no requirement for the precursor 
3CD that had previous been demonstrated as necessary for PV uridylylation.  
They also identified residues within the 3C protein that interact with the cre and 
are essential for VPg uridylylation. 
1.5.4.2     3D RNA Polymerase 
 The FMDV 3D protein is a RNA-dependent-RNA-polymerase and is 
required to produce both positive- and negative-sense viral RNA.  An excess of  
positive sense strands accumulate within infected cells in comparison to 
negative sense strands. To achieve this, it is presumed that the RNA 
polymerase differentially identifies the negative sense template over the positive 
sense template.  The 3’ terminus of the positive-sense RNA contains a poly (A) 
tail while the negative RNA ends with an anti-sense S-fragment.  These are 
significantly different in sequence from each other.  Investigation of PV initiation 
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of negative-strand synthesis produced evidence of a Poly (A) binding protein 
(PABP)-3CD complex and a PCBP-3CD complex that interacted with each 
other to create a circular RNP complex (Barton et al., 2001; Herold and Andino, 
2001).  The 3’ UTR of FMDV has two stem loops which are thought to interact 
with the S-fragment and the IRES, which infers that the 5’ and 3’ UTRs could be 
involved in similar process (Serrano et al., 2006). 
In the case of FMDV, the 3CD intermediate does not possess RNA 
polymerase activity.  In PV the 3CD binds to the 5’ cloverleaf structure on the 
PV genome (Gamarnik and Andino, 1998) and is required in the cre-dependant 
VPg uridylylation assay (Paul et al., 2000). Currently, no specific function has 
been identified for the FMDV 3CD protein as 3C alone is sufficient for 
polyprotein processing. 
1.5.5 FMDV 3’ UTR 
 The FMDV 3’ UTR consists of two components: a 100nt heterogeneous 
sequence that is predicted to fold into a stem loop structure (Pilipenko et al., 
1992) and a poly (A) tail.  The poly (A) tail is part of the viral genome, which is 
different to cellular mRNAs where the polyA tail is added post-transcriptionally 
(Dorsch-Hasler et al., 1975).  Little is known about the FMDV 3’ UTR, although 
it has been shown to be required for  infection (Saiz et al., 2001) and stimulates 
translation by the IRES (Lopez de Quinto et al., 2002).  Evidence also suggests 
that RNA-RNA interactions occur between the 5’ and 3’ UTRs of the genome 
and that the ends of the genome are bridged via RNA-protein interactions.  This 
circularisation of the genome may be required to maximise virus replication.  In 
respect to this, the poly-A tract would be expected to bind PABP to form the 
bridge between the 5’ and 3’ ends in the presence of other viral/host proteins 
(Barton et al., 2001; Herold and Andino, 2001).  The terminal A residues could  
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 Figure 1.3 FMDV genome organisation and Polyprotein processinTranslation is initiated via 
the IRES to produce the FMDV polyprotein that is co-translationally cleaved by virus encoded 
proteases into structural and non-structural proteins (P1, P2 and P3). These are further 
processed to produce a number of precursors and mature proteins which have important 
functions in virus replication.  In total, 15 different mature proteins are produced. Thick lines 
below the genome show partial cleavage products.  Open boxes indicate protein encoding 
regions, lines indicate RNA structure (Mason et al., 2003).
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also provide a template for the VPg-pUpU primer to allow negative strand 
synthesis (Saiz et al., 2001). 
 
1.6 The viral life cycle 
(See Figure 1.5) 
1.6.1 Attachment and Entry  
Picornaviruses employ a variety of strategies to enter cells.  For many 
Picornaviruses, entry requires a major conformational change to the capsid to 
form an A (altered) particle, as a prerequisite for releasing their viral RNA.  For 
many viruses e.g. Enteroviruses and several major-receptor group human 
rhinoviruses (HRV), this structural transformation is mediated by binding of 
specific cellular receptors into the viral canyon (Arita et al., 1998; He et al., 
2000; Powell et al., 1997).  As mentioned previously, (in sections 1.3 and 1.5.2) 
there is no conclusive evidence of A particle formation of the FMDV capsid, and 
FMDV uncoating is believed to proceed straight to 12S pentamer subunits, RNA 
and VP4 (Baxt and Bachrach, 1980, 1982; Brown and Cartwright, 1961; Curry 
et al., 1996). FMDV can use several αv integrins (αvβ1,αvβ3, αvβ6, and αvβ8) 
as receptors to gain entry into cells (Berinstein et al., 1995; Jackson et al., 
2004; Jackson et al., 2002; Jackson et al., 2000)  The integrin of primary 
interest is αvβ6, as this integrin has been shown to be expressed on the 
epithelial cells targeted by FMDV in cattle, and to bind to the RGD motif on the 
GH loop of VP1 (see section 1.3) with a higher affinity than the other integrin 
receptors (Burman et al., 2006).  The integrin-binding loop of FMDV forms a 
stable, EDTA-resistant complex with αvβ6 (Dicara et al., 2008) which is 
believed to trigger internalisation of the virus-integrin complex into the cell.    
37
Berryman et al (Berryman et al., 2005) observed that the virus co-localised with 
both early- and recycling-endosomes, but not lysosomes, upon entry.  In 
addition, infection was not affected by nocodazole, a reagent that prevents 
vesicular trafficking between early- and late-endosomes. This was consistent 
with a study that found FMDV infection levels were significantly reduced in cells 
expressing dominant-negative mutants to Rab5, a regulator of endosomal traffic 
(Johns et al., 2009). This evidence combined with the finding of the presence of 
the integrin receptor αvβ6 in both early and recycling endosomes, shows that 
FMDV enter cells via clathrin-dependant endocytosis (Berryman et al., 2005; 
O'Donnell et al., 2005).   
It has been observed that tissue culture adaptation of some serotypes of 
FMDV results in the selection of viruses that bind heparan sulphate and that are 
consequently attenuated in the host (Sa-Carvalho et al., 1997).  The HS-binding 
FMDV was also found to be taken into the cell by early endosomes, although 
evidence suggests this is via a caveola-mediated pathway (O'Donnell et al., 
2008), suggesting entry of FMDV into cells is dependent on the viral receptor. 
 Once within endosomes, the prevailing low pH triggers capsid 
disassembly and the translocation of the viral RNA across the endosomal 
membrane into the cytosol. To date, the mechanisms of release of the vRNA 
into the cytoplasm still remain largely unknown.  A number of studies have 
looked at the release of vRNA in Human Rhinoviruses (HRV).  There are over 
100 serotypes of HRV which are grouped according to their receptor usage 
(Uncapher et al., 1991).  HRV-2, a minor group HRV that uses the low-density 
lipoprotein receptor [LDLR] as a receptor (Hofer et al., 2004; Marlovits et al., 
1998), has been found to have the ability to form a pore in the endosomal 
membrane through which vRNA could potentially be released (Danthi et al., 
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2003; Prchla et al., 1995). In contrast, HRV-14, a major group HRV, which uses 
the intercellular adhesion molecule 1 [ICAM] as a receptor (Uncapher et al., 
1991;Tomassini et al., 1989) was shown to release subviral particles into the 
cytosol by the total disruption of the endosomal membrane, in a similar manner 
to Adenoviruses (Prchla et al., 1995).  For PV the capsid proteins VP1 and VP4 
have been implicated in endosomal penetration.  VP4 and the N-termini of VP1 
become exposed on A-particle formation.  In PV, this rearrangement creates 
135S particles that interact with membranes via the hydrophobic N-terminals of 
VP1, which are able to form ion channels within lipid bilayers (Danthi et al., 
2003).    It has also been demonstrated that the VP4 of PV is associated with 
cellular (Danthi et al., 2003) and liposomal membranes (Tuthill et al., 2006) 
during the initial stages of infection.  Mutants lacking VP4 sequences prevent or 
alter ion channel formation which results in the delay or prevention of the 
release of the viral genome into the cytosol (Danthi et al., 2003; Knipe et al., 
1997). As Aphthoviruses do not form an A particle it remains unknown how 
these viruses interact with cellular membranes.   
1.6.2 Translation
Once within the cytosol, the VPg cap is removed from the 5’ end of the 
viral genome by cellular host factors and the intracellular phase of replication is 
initiated.  The vRNA functions sequentially as a template for the synthesis of the 
viral proteins (translation) and then of complementary negative-strand genome 
copies. The negative strands are then used as a template for the synthesis of 
new progeny positive-sense genomes (genome replication).    
Positive-stranded RNA is translated directly by the cells translation 
machinery.  On infection, most picornaviruses cause the shut-down of host cell 
translation to allow the production of viral proteins to take precedence. For  
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Figure 1.4 FMDV translation 
Initiation factors are recruited near the IRES 3’ end to guide the ribosome downstream 
of the IRES.  Cellular translation factors including eIF4G, B and A bind to 3’ region of the IRES.  
The small ribosomal subunit binds to the complex at the IRES.  The eIF4G complex is believed 
to bind with the ribosome bound eIF3 and eIF4B and the 60s ribosomal unit is recruited initiating 
translation of the viral genome (Saleh et al., 2001) 
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FMDV this is achieved through the cleavage of the cellular translation 
factor eIF4G by the viral proteases L (Leader) and 3C (see sections 1.4 and 
1.5).  Cellular mRNA translation requires a 7-methyl guanine (m7G) 5’ cap 
which interacts with an intact eIF4F complex for translation initiation (Shatkin, 
1976).  The eIF4F complex consists of 3 proteins: eIF4E which binds to the 5’ 
cap, eIF4A which has helicase activity and binds to the mRNA and eIF4G which 
acts as a bridging protein between the two components (Gingras et al., 1999).  
The complex also recruits eIF3, which binds to the 40S ribosomal subunit and a 
tRNA that binds to the complex via eIF2.  This creates a 48S pre-initiation 
complex which acts as a bridge between the mRNA and the 40s ribosomal 
subunit.  The complex scans along mRNA until it reaches an appropriate AUG 
codon that can be used for the initiation of translation (Kozak, 1989).  Once 
initiated, the 60S ribosomal subunit joins to create the 80S complex, the 
initiation factors disassociate and translation can begin (Hershey, 2000).  In 
contrast, FMDV translation only requires the L generated C-terminal region of 
eIF4G which interacts with 40S ribosomal subunit-bound proteins EIF4A and 
eIF3 (Lopez de Quinto and Martinez-Salas, 2000; Saleh et al., 2001).  This 
complex along with eIF4B, eIF3 and eIF2 bind directly to the FMDV IRES which 
is responsible for internally initiating the translation of FMDV RNA (Belsham et 
al., 1990; Martinez-Salas et al., 1993). IRES activity is also modulated by other 
cellular RNA-binding proteins, such as the polypyrimidine tract-binding protein 
(PTBP) (Lopez de Quinto and Martinez-Salas, 2000; Meyer et al., 1995; Ochs 
et al., 1999; Rust et al., 1999) and ITAF45.  Both of these proteins are required 
for the formation of the 48S initiation complex (Martinez-Salas et al., 2001; 
Pilipenko et al., 1992).  Cellular PCBP, is also required for PV RNA translation, 
however this has not been shown to play a role in FMDV translation.  
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Nonetheless, the poly (C) tract upstream of the IRES may suggest it plays a 
part in FMDV translation/replication.  PCBP in PV is thought to aid the 
circularisation of the genome to switch from translation to replication (Barton et 
al., 2001; Herold and Andino, 2001).  The 3’ end of the FMDV genome may also 
be required for FMDV translation, as deletion of the poly(A) alone or both the 3’ 
stem loop and poly(A)  resulted in non-infectious  FMDV RNA with a lower 
translation in vitro (Lopez de Quinto et al., 2002) (see Figure 1.4). 
1.6.3 Replication
FMDV viral RNA replicates with a high efficiency in susceptible cells and 
a large amount of full-length viral RNA is produced within 4-6 hours post 
infection.  An excess of positive strand RNA is produced in infected cells when 
compared to negative strands. Viral RNA is synthesised by the RNA-
dependant-RNA-polymerase (3Dpol), which is encoded within the viral genome; 
additional viral proteins are also required to initiate this process.  VPg (3B) acts 
as a primer to initiate RNA synthesis within a membrane associated complex 
that contains a number of additional viral proteins (see section 1.4.4).  A switch 
in function of the viral RNA inhibits translation to enable RNA replication to 
proceed.  The switch is required as the translation process of the viral RNA is 
not compatible with the movement of RNA polymerase from the 3’ end to the 5’ 
terminus (Gamarnik and Andino, 1998).  The molecular mechanisms that result 
in a switch from translation to replication are uncertain but a model has been 
proposed for Poliovirus.  During translation the PV genome is thought to 
become circularised through an interaction of the 5’ cloverleaf, PCBP2 and 3CD 
at one end of the genome with PABP bound to the 3’poly(A)  at the other 
(Barton et al., 2001; Herold and Andino, 2001; Lyons et al., 2001; Teterina et 
al., 2001).  The circularisation has been proposed to prevent the binding of 
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initiation factors and ribosomes to the 5’ of the IRES, therefore the vRNA would 
eventually become clear of all ribosome’s and the template for negative strand 
synthesis could be utilised (Barton et al., 2001).  A similar model could be 
possible for FMDV since it has been proposed that FMDV can circularise its 
genome through the interaction of PCBP and the 5’ UTR poly(C) tract, along 
with PABP bound to the 3’ poly(A) tail (Mason et al., 2002) (see section 1.5.5). 
Both negative- and positive-strand synthesis is initiated by the virus 
encoded VPg (3B) primer and 3Dpol. It is also thought that several other viral 
non-structural proteins as well as host proteins might be part of this process.  
The VPg (3B) peptide acts as a primer for both negative- and positive- strand 
synthesis.  FMDV, unlike other picornaviruses encodes three tandem copies of 
VPg that are distinguishable from each other but all have been found to interact 
with vRNA (King et al., 1980). VPg becomes uridylylated by the virus- encoded 
3Dpol to create a pool of uridylylated VPg consisting of two forms: VPgpU and 
VPgpUpU.  Uridylylation is reliant on the cre element located at the 5’ UTR of 
the FMDV, UTP, divalent cations, 3D and its precursor 3CD in vitro (Nayak et 
al., 2005) (see section 1.4.4)  Although all three copies of VPg can be 
uridylyated in vitro, the reaction is more efficient using the third copy.  In 
addition, the efficiency of uridylylation is enhanced when the entire 5’ UTR is 
utilised in the reaction as opposed to the cre alone (Nayak et al., 2005). 
Poliovirus negative-strand synthesis has been proposed to occur 
following the translocation of VPgpUpU from the cre to the 3’ poly(A) tail on a 
positive sense genome (Paul et al., 2000) (see section 1.4.4).  Base-pairing of 
the VPgpUpU with the poly(A) would result in the synthesis of the negative  
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 Figure 1.5 The Picornavirus Replication cycle  
Viral entry is by receptor-mediated endocytosis which leads to the release of the 
positive-sense RNA into the cytoplasm. This RNA is translated into a large polyprotein and 
cleaved by virus encoded proteases. Viral proteins cause host cell membrane rearrangements 
to form replication complexes which allow viral replication to proceed. Newly synthesized 
positive-sense RNA is also translated and the process repeats until sufficient capsid protein 
precursors are formed, to allow assembly of the procapsid. Procapsids associate with newly 
synthesized positive-sense RNA still containing VPg at its 5’ end.  As the process continues, 
virions accumulate in the cytoplasm until viral proteins induce cell lysis and virus release occurs 
(E.K.Wagner, 2004). 
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strand genome from the positive strand copy by 3Dpol, using VPgpUpU as a 
primer (Paul et al., 2000).  Alternatively, a more recent study showed evidence 
that negative strand synthesis does not depend on the cre structure in vitro, as 
mutations within the AAACA motif required for uridylylation did not inhibit 
negative strand synthesis (Goodfellow et al., 2003b; Morasco et al., 2003; 
Murray and Barton, 2003).  This suggests that the unmodified VPg may prime 
the 3Dpol, not VPgpUpU (Morasco et al., 2003).  This model predicts that the 
poly(A) acts as a template for uridylylation of VPg by 3Dpol, to create VPg 
poly(U) which extends to create a full length negative sense-strand copy. This 
was strengthened by the fact that 3D, VPg, UTP Mg2+ and poly(A) results in 
VPg-poly(U) formation (Paul et al., 1998).  The initiation of positive strand 
synthesis is believed to occur at the 3’terminus of the RNA template, as an 
authentic 5’ end of the PV genome is required for positive strand synthesis by 
3Dpol (Herold and Andino, 2000). 
1.6.4  Replication Complexes 
Picornavirus infection results in the extensive rearrangement of the host 
cell membranes, creating replication vesicles that are necessary for viral 
genome replication (Bienz et al., 1983; Dales, 1965; Gosert et al., 2000; Gosert 
et al., 2002). These membranes are believed to function as “platforms” to 
facilitate the assembly of viral replication complexes (RC) containing the correct 
balance of replicase proteins (see Figure 1.6). The 2C, 2B and 3A proteins of 
enterovirus are believed to be important components of the RC.  The 2C and 2B 
proteins have been shown to bind membranes via amphipathic helices (Paul et 
al., 1994), whereas poliovirus 3A and its precursor 3AB interact with 
membranes through a hydrophobic region of 3A (Towner et al., 1996). 
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Membrane rearrangements have been extensively studied for poliovirus 
(Bienz et al., 1983), echovirus (Skinner et al., 1968) and coxsackievirus A 
(Jezequel and Steiner, 1966), and membranes from several cellular 
compartments have been associated with formation of replication vesicles..  
Early studies concluded that, PV-induced vesicles are derived from the 
endoplasmic reticulum (ER) (Schlegel et al., 1996; Suhy et al., 2000), at sites 
enriched for the COPII protein complex (Rust et al., 2001).  COPII coated 
vesicles normally play key roles in vesicular transport between the ER and the 
Golgi (see section 1.8.1).  In the later stages of PV infection, membranes from 
other cellular organelles were implicated in vesicle formation, namely the Golgi 
and lysosomes (Bolten, 1998).  Although different genera of picornaviruses 
share similar replication strategies, research has highlighted many important 
variations: specifically, that replication can occur on vesicles derived from 
different membranes and at varying sites around the cell (Gazina et al., 2002).  
PV, EV11 and EMCV all appear to induce similar rearrangements of the host 
cell membranes by forming heterogeneously sized vesicles (200-400nm) 
arranged in tight clusters.  Conversely, HPEV-1 has been observed forming 
uniform vesicles present in a low number, and in loose arrangements (Gazina et 
al., 2002). Viral RNA has been shown to be associated with these membranes 
(Bienz et al., 1980; Butterworth et al., 1976; Caliguiri and Tamm, 1970) and 
replication is thought to take place on the outer cytoplasmic surface (Bienz et 
al., 1987).  Formation of vesicles can be recreated by the expression of 
poliovirus 2BC and 3A proteins in transfected cells.  These vesicles shared 
similar biochemical and morphological characteristics to naturally infected cells 
(Suhy et al., 2000).  PV vesicles are also noted to share structural similarities 
with autophagosomes, for example they possess a double membrane and 
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contain cytoplasmic material (Schlegal et al., 1996), which may suggest a role 
for autophagy in PV replication.  
FMDV infection of BHK-38 cells causes single membrane vesicles, which 
appear in loose clusters and are fewer in number than in poliovirus infected 
cells. The entire cellular cytoplasmic contents become condensed and localised 
to a region on one side of the nucleus. This region contains both viral proteins 
and vRNA in addition to areas of tightly packed ribosomes and smooth 
cytoplasmic structures located at perinuclear sites.  The viral non-structural 
protein 2C was found to co-localise with VP1, 3A and 3D within this region, but 
not proteins associated with the secretory pathway (Knox et al., 2005). This 
finding suggests that FMDV may not use the secretory vesicles for the 
formation of replication complexes. Alternatively, FMDV replication complexes 
may form on secretory vesicles, but the markers for these vesicles may be 
rapidly excluded from the replication complex (Moffat et al., 2005). As 
previously mentioned, all Picornaviruses rely on host cell membrane 
rearrangements (Miller and Krijnse-Locker, 2008; Richards and Ehrenfeld, 
1990; Salonen et al., 2005), however it is the properties of the RCs that allow 
viral replication to proceed.  It has been proposed that the membranes may 
serve to increase the local concentration of viral and host proteins, and vRNA at 
sites of replication, or that the lipid composition of the membrane maybe 
required for replication to proceed (Miller and Krijnse-Locker, 2008).  The most 
recent studies on the formation of RC’s in enteroviruses have implicated the 
recruitment of phosphatidylinositol 4-kinases to RC membranes.  
Phosphoinositides are cellular phospholipids that are important in the regulation 
of the recruitment and the activity of signalling proteins on cellular membranes.  
As mentioned (see section 1.10.3), PV and CVB3 both require the activity of  
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Figure 1.6 Replication complexes 
The above figure shows the ultrastructural changes in cells at mid-stages of infection with 
FMDV observed at high power. (a) Large numbers of membrane vesicles are present (arrow) 
within the replication complex. These are often associated with membranes and have the 
appearance of ribosome-depleted rER. (b) Occasionally double membrane vesicles are seen 
(see black arrow) (c) A large numbers of ribosomes are present in linear patterns within the 
replication complexes. (Monaghan et al., 2004).  
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GBF1, which recruits Arf1 onto host cell membranes. This in turn results in the 
recruitment of various effectors (Altan-Bonnet et al., 2004; Niu et al., 2005).  
Arf1 effectors include COPI proteins (see section 1.8.2) that regulate vesicle 
budding, and phosphatidylinositol-4-kinase IIIPI4KIIIwhich generate 
phosphatidyl-inositol-4-phosphate (PI4P) lipids at the membrane bilayer (Altan-
Bonnet et al., 2004; Godi et al., 2004; Lee, 2004).  PI4P lipids have been 
reported to regulate ERES biogenesis and autophagy (Blumental-Perry et al., 
2006; Yamashita et al., 2006) and alter membrane curvature (Ishiyama et al., 
2002; McMahon and Gallop, 2005).  Hsu et al (Hsu et al., 2010) have proposed 
a model showing that enteroviral 3A binds to membranes and recruits host cell 
proteins GBF1 and Arf1, which in turn preferentially recruit PI4KIII to host cell 
membranes.  The recruitment of PI4KIIIresults in the production of PI4P 
leading to the creation of lipid rich membranes, which are distinct from host cell 
membranes.  These lipid rich ‘microenvironments’ then promote the recruitment 
of viral proteins involved in viral replication such as 3Dpol, which was shown to 
preferentially bind to PI4P lipids, to create the RC.  The preferential recruitment 
of PI4KIIIonto membranesover COPI would result in a block in transport 
within the early secretory pathway and disruption of the Golgi, as has been 
observed in enterovirus infected cells.   
1.6.4.1 Brefeldin A 
An important difference in picornavirus replication is the sensitivity to 
brefeldin A (BfA).  Brefeldin A is an inhibitor of membrane transport in the 
secretory pathway between the ER and Golgi. It prevents the formation of COPI 
vesicles which are necessary for secretory transport (Doedens and Kirkegaard, 
1995; Rothman, 1994) (see section 1.8.2).  Infection by PV, EV11 and BEV 
(bovine enterovirus) are all significantly inhibited by brefeldin A (Maynell et al., 
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1992). Brefeldin A acts by preventing the activation and function of a small 
family of GTPases, specifically Arf GTPases, by inhibiting the guanine 
nucleotide exchange factor (GEF), and recycling Arf1 from an inactive GDP 
bound state to an active GTP bound form (Mossessova et al., 2003).  The ability 
of BFA to inhibit PV infection suggests that viral replication relies on Arf-
dependent membrane trafficking. Components of the COPI coat complex are 
recruited to membranes by activated Arf1. One of the components has been 
shown to localise to replication complexes in cells infected by Echovirus 11, 
which, like Polioviruses, is sensitive to BFA (Maynell et al., 1992).  Arf1 was not 
however, detected on replication complexes of viruses such as EMCV or FMDV 
which are resistant to BFA (Gazina et al., 2002). 
1.7 Particle assembly, maturation and release 
The final stages in the replication cycle of FMDV involve encapsidation of 
the vRNA genome and cleavage of VP0 to create VP2 and VP4 to form the 
mature virion that is released from the cell (see Figure 1.7). 
The building block of the capsid is a protomer formed by one copy of VP0, 
VP1 and VP3.  Pentamers (12S) are formed by the association of five 
protomers. Then 12 pentamers associate to form the final acid sensitive capsid.  
On encapsidation of the vRNA, VP0 is cleaved to form the mature particle.  
Several other possible forms of particles have been observed during infection: 
RNA containing particles that have not undergone VP0 cleavage (provirion) 
(Guttman and Baltimore, 1977; Lee et al., 1993) and empty capsids (Grubman 
et al., 1985; Yafal and Palma, 1979).  It remains uncertain what signals are 
required for RNA encapsidation.  Picornaviruses only encapsidate positive 
strand RNA linked to VPg (Nomoto et al., 1977; Novak and Kirkegaard, 1991; 
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Wimmer, 1982) and only newly synthesised +ve vRNA is packaged, suggesting 
there is a link between active replication and encapsidation (Harber et al., 1991; 
Nugent et al., 1999).  Recent studies have shown that PV 2C protein directly 
interacts with VP3 at RC’s, implying a role for 2C in encapsidation (Liu et al., 
2010).  There are two models for capsid assembly in picornaviruses.  The first 
suggests pentamers assemble and the RNA is inserted into empty capsids, the 
second proposes that pentamers interact with RNA directly to form a provirion.  
FMDV studies showed that radioactive labelled structural proteins were found in 
protomers, pentamers, empty capsids and virions (Yafal and Palma, 1979), 
reinforcing the first models proposal.  Contrary to this, Verlinden et al (Verlinden 
et al., 2000)   agreed with the second model, producing evidence for pentamers 
interacting with RNA to produce virions in poliovirus cell-free systems.    
Once the vRNA is encapsidated myristylated VP0 (see section 1.5.2) is 
cleaved to create a mature capsid. It is thought FMDV vRNA plays a role in this 
process as cleavage is more efficient in natural particles as opposed to 
artificially formed virions (Curry et al., 1995; Curry et al., 1997). The cleavage is 
believed to be autocatalytic, and produces a more stable particle by increasing 
the ordering of the structural protein’s N-termini which is due to the presence of 
RNA (Curry et al., 1997).  Site directed mutagenesis studies of FMDV VP0 
produced non-infectious virus particles, but the particle retained its receptor 
binding and acid sensitivity properties.  This provirion’s pentamers appeared to 
be more hydrophobic after acid dissociation than mature virions, suggesting that 
VP0 cleavage might be necessary for RNA translocation into the cytosol (Knipe 
et al., 1997). 
Finally, the newly formed virus particle is released from the host cell.  
Infection of cultured cells results in cell lysis and plaque formation, suggesting  
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Figure 1.7 Assembly and release 
Capsid proteins are cleaved from the polyprotein by 2A protease as a monomer, 3C 
cleaves the protein further into protomers (VP0, VP3 and VP1).  Five protomers assemble to 
form a pentamer and 12 pentamers form the Procapsid.  After RNA encapsidation the VP0 is 
cleaved into VP2 and VP4 to create the final virion. (E.K.Wagner, 2004)  
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the release of progeny virus is via cell lysis of infected cells (Belsham, 1993).  
Poliovirus 3A protein has been implicated in the lysing process (Lama et al., 
1998), although the mechanism for this is largely unknown.   
 
1.8 The early secretory pathway 
Eukaryotic cells possess a secretory pathway consisting of a complex 
endomembrane network containing several organelles that function to transport 
proteins to the plasma membrane and the extracellular environment (Lee, 
2004).  Newly synthesised proteins enter the system via the rough endoplasmic 
reticulum (ER) by the action of ribosome docking proteins onto pores on the ER 
membrane. Docking results in the release the polypeptide into the ER lumen, 
once inside, chaperones fold proteins into their correct formation and post-
translational modification occurs.  Transport vesicles bud from the ER- 
containing cargo at ER exit sites (ERES) and fuse together to form the ER-Golgi 
intermediate compartment (ERGIC) (Orci et al., 1982). The ERGIC gives rise to 
the cis-Golgi which accepts incoming transport vesicles, proteins are then 
processed in the medial-Golgi before being packaged and exported to their 
required destination via the trans-Golgi network (see Figure 1.8).   
 Coatomer complex proteins (COP) are essential for transport between 
organelles.  COP II proteins are responsible for the initial anterograde transport 
from the ER, in vesicles containing cargo and SNARES (soluble NSF 
attachment protein receptor).   It was initially thought that COPII existed as free 
vesicles that moved along microtubules to the Golgi.  However, it is now 
believed that COPII vesicles rapidly lose their coat after budding from ERES 
(Oka and Nakano, 1994).  Morphological analysis in mammalian cells showed 
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that COPII vesicles undergo fusion to create vesicular tubular clusters (VTC) 
also known as the ER-Golgi intermediate compartment (ERGIC).  These 
vesicles are distinct from the ERES but are still interconnected (Bannykh et al., 
1996). Both COPI and COPII vesicles have been found associated to the 
ERGIC (Aridor et al., 1995; Scales et al., 1997). Recently, evidence has shown 
that COPII components appear to be tightly associated to the ERES and are 
relatively immobile.  COPI is seen to form in close proximity to COPII sites 
before detaching and moving towards the cis-Golgi, whereas COPII remains at 
or near the ERES. This suggests a sequential mode of action between the two 
vesicles (Shima et al., 1999; Stephens and Pepperkok, 2002).  COPI transports 
proteins onto the cis-Golgi and is also involved in the retrograde transport of 
proteins back to the ER.   
The formation and targeting of the transport vesicles relies on a complex 
sequence of interactions involving regulatory molecules. Cargo marked to leave 
a compartment is incorporated into a transport vesicle via a direct or indirect 
interaction with cytoplasmic proteins. These proteins become concentrated on 
the membranes of the donor compartment to form a coat; assembly of such 
complexes induce the formation of a transport vesicle on the donor membrane. 
The docking and fusion of vesicles with the acceptor organelle membrane 
involves interactions with the actin and microtubule cytoskeleton, recruitment of 
docking complexes and the specific recognition between v- and t-SNARES. 
Small GTPases of the ADP-ribosylation factor (Arf) and Rab family have been 
implicated as regulators of these events (Chavrier and Goud, 1999). Proteins 
that are secreted from the cell are modified and matured in the Golgi before 
vesicles transport the proteins to the plasma membrane. 
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1.8.1 COPII formation  
COPII vesicle formation occurs on the smooth ER membranes at ER exit 
sites (ERES) where cargo for export is concentrated (Bannykh et al., 1996). The 
ERES are ribosome free subdomains specialised for COPII formation, which 
are relatively long-lived and distributed throughout the ER (Aridor et al., 2004; 
Bannykh et al., 1996; Bevis et al., 2002; Stephens, 2003). 
Assembly of the COPII coat is initiated through the activation of the small 
Ras-like GTPase, secretion-associated Ras-related 1 (Sar1) (Nakano et al., 
1988).  As with all GTPases, Sar1 is bound to GDP in the cytosol, where it is 
inactive; it is converted to active GTP-bound form by a guanine nucleotide 
exchange factor (GEF).  Sec12 is the known GEF for Sar1 (Barlowe and 
Schekman, 1993; Nakano et al., 1988) which is localised to the ER, therefore 
Sar1 activation is restricted to this area of the early secretory system (Sato et 
al., 1996).  The conformational change of Sar1 from the GDP-bound form to the 
GTP-bound protein exposes the N-terminal, amphipathic α-helix of the protein 
that inserts into the ER membrane (Bi et al., 2002; Huang et al., 2001).  
Membrane bound Sar1-GTP recruits a Sec23-Sec24 heterodimer by binding to 
Sec23, together the complex Sec23/24-Sar1 selects cargo to form a pre-
budding complex (Kuehn et al., 1998). Once formed the pre-budding complex 
recruits Sec13-Sec31 heterotetramer to form an outer coat (Lederkremer et al., 
2001). Evidence shows Sec13/31 can assemble into a cage-like structure in the 
absence of other components of the COPII complex (Stagg et al., 2006). 
Sec13/31 incorporated into the pre-budding complex is thought to stabilise the 
coat during polymerisation and drive membrane deformation to form COPII 
vesicles (60-70 nm in diameter).  Several studies have implied a role for the 
Sec16 protein in vesicle budding. Sec16 is a large peripheral protein found 
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associated with ER membranes (Espenshade et al., 1995).  Sec16 domains 
make direct contact with the COPII proteins Sec23 and Sec31, which are 
thought to act as a scaffold for coat assembly, and thus have a role in ERES 
formation (Gimeno et al., 1996; Supek et al., 2002).  However, it remains 
unclear if Sec16 is required for ERES organisation and/or COPII vesicle 
formation (see Figure 1.9). 
The majority of membrane and soluble cargo proteins in the ER are 
concentrated in COPII vesicles.  COPII efficiently recognises and sorts cargo 
from ER resident proteins for incorporation into vesicles (Barlowe et al., 1994; 
Salama et al., 1993).  Cargo is selected through export signals within the 
exposed amino acid sequence of the proteins (Barlowe, 2003).  In many cases 
the export signals of transmembrane proteins are believed to bind directly with 
the COPII vesicle complex Sec23/24 (Aridor et al., 1998; Kuehn et al., 1998) 
through the Sec24p subunit (Miller et al., 2003; Mossessova et al., 2003), 
however some transmembrane and soluble proteins are thought to bind via 
transmembrane cargo adaptors/receptors. 
COPII vesicles shed their coat rapidly after exit from the ER and it is 
replaced by COPI (see section 1.8.2), before fusing with the ERGIC membrane 
through Sar1-GTP hydrolysis (Oka and Nakano, 1994). This releases cargo 
from the sorting subunits along with COPII proteins to be recycled back to the 
ER. GTP hydrolysis is mediated by GTPase activating proteins (GAPS).  GAPs 
encourage GTP hydrolysis and therefore reverse the Sec23/24-Sar1 interaction.  
Sec23 of Sec23/24 is the GAP for Sar1 (Yoshihisa et al., 1993); this activity is 
further stimulated (~10 fold) by the binding of Sec13/31subunit (Antonny et al., 
2001). The Sec23 activity on Sar1 is commonly used by other GAPs of the Ras 
super-family: an arginine finger interacts with a Sar1 catalytic site to neutralise 
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the negative charge that occurred in the GTPase transition.  In order to maintain 
stable vesicles Sec23/24 is held on the membrane by the GEF Sec12 which 
counteracts the GAP activity by constantly supplying Sar1 with GTP (Futai et 
al., 2004).   
Sar1 is thought to be the component required for the initial stages of 
membrane deformation and vesicle fission as there is evidence that Sar1 alone 
is sufficient to deform liposome membranes (Lee et al., 2005).  The insertion of 
the Sar1 N-terminal helix into the ER membrane would act to displace the lipid 
head-groups causing curvature towards the cytoplasmic side (Farsad and De 
Camilli, 2003; Sheetz and Singer, 1974).  The addition of Sec23/24 and 
Sec13/31 components results in coat polymerisation; as the coats assemble, 
the GAP’s hydrolyse the GTP.  The energy of polymerisation then causes 
deformation of the membrane and leads to vesicle scission (Barlowe, 2000). 
1.8.2 COPI formation 
Coatomer (COPI) is composed of seven conserved subunits and its 
formation is controlled by the GTPase Arf1.  Arf1 has the ability to induce 
membrane formation at several points along the early secretory pathway by 
interacting with numerous GEFs which are involved in Arf1 activation and 
recruitment onto membranes.  All of the GEFs known to associate with Arf 
share a Sec7 domain that is involved with exchange activity. They are present 
in two forms, either resistant or sensitive to the fungal metabolite brefeldin A 
(Jackson and Casanova, 2000; Peyroche et al., 1996), which allows the 
detailed study of GEF activity on Arf1.  Different interactions of Arf with GEFs 
could determine which membrane the protein associates with (Chantalat et al., 
2003; Chantalat et al., 2004; Richter et al., 2007; Spang et al., 2001).  ARF-
GDP has been found to be recruited directly to the membrane by an association 
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with p23 (an integral membrane protein), where GDP is exchanged for GTP by 
GEFs (Gommel et al., 2001; Majoul et al., 2001).  Once Arf1-GDP has been 
catalysed by a GEF to Arf-GTP it is able to interact with Arf-GAP and 
cargo/SNARE proteins.  The GAP does not stimulate GTP hydrolysis at this 
point, but instead plays a role of inducing a conformational change in SNARE 
proteins which allows a direct interaction with Arf1, this in turn aids the 
recruitment of the heptameric protein complex called the coatomer (Rein et al., 
2002; Schindler and Spang, 2007; Spang, 2002).  The coatomer consists of 
seven subunits that include:  α, β, β’, γ, δ, έ, ζ   (Waters et al., 1991), Arf and 
p24 family membrane proteins.  Coatomer subunits are directly involved in the 
recruitment of cargo into the COPI vesicles through dilysine motifs usually 
containing a KKXX or KXKXX (K = lysine and X= arginine or alanine) sequence 
at the carboxyl terminus of type 1 transmembrane proteins (Cosson and 
Letourneur, 1994).  The interaction between the motifs and vesicle is necessary 
for retrograde transport (Letourneur et al., 1994).  Three of the coatomer 
subunits (β, γ and δ) have been identified in cargo recognition and all bind to 
different motifs (Michelsen et al., 2007). By recruiting these proteins into the 
COPI vesicle, the membrane deforms to form the vesicle. 
Stimulation of Arf1-GAP activity was observed after binding of the 
coatomer complex (Goldberg, 1999) and the incorporation of specific cargo 
such as KDEL receptors (Aoe et al., 1997).  Like Sar1, Arf-GAP is part of the 
COPI coat (Lee et al., 2005; Lewis et al., 2004; Yang et al., 2002) and it is 
therefore likely GTP hydrolysis is regulated in a similar manner.  COPI coat 
disassembly is also thought to stimulate membrane curvature (Bigay et al., 
2003; Mesmin et al., 2007) in the Golgi. 
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Figure 1.8  A model of transport between the endoplasmic reticulum (ER) and Golgi 
compartments. 
After translation and folding of secretory proteins, fully folded cargo and soluble secretory cargo 
are exported from the ER in (COPII)- formed transport vesicles. COPII vesicles transport 
proteins in an anterograde direction to fuse with or form the ERGIC. COPI coats provide 
retrograde transport from the ERGIC and Golgi compartments to recycle ER resident proteins 
(R) back to the ER (Dancourt and Barlowe, 2010). 
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Figure 1.9  A model for coat protein complex II (COPII)-dependent cargo selection and 
vesicle formation.  
Sar1 is activated by the nucleotide exchange factor (GEF) Sec12 to Sar1-GTP. Membrane-
bound Sar1-GTP recruits Sec23-Sec24 to assemble pre-budding cargo complexes within which 
the Sec24 subunit binds to specific sorting signals on export cargo. Cargo can link to the Sec24 
subunit directly or through transmembrane sorting receptors. Pre-budding cargo complexes 
recruit the Sec13-Sec31 complex, leading to coat polymerization and vesicle formation 
(Dancourt and Barlowe, 2010). 
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1.8.2.1 Sar1 and Arf proteins 
Sar1 is a unique family within the Ras super-family of small GTPases 
and only has around a 37% homology to its closet relative Arf1. Sar1 is present 
as two isoforms, Sar1a and Sar1b, they differ by approximately 20 amino acids 
at the C-terminus, but no separate functions have been assigned to the different 
isoforms (Charcosset et al., 2008).  The majority of GTPases possess cysteine 
residues at their c-terminus that are modified and Arf1 has a myristolated N-
terminus, in contrast Sar1 does not undergo any posttranslational modifications 
at either terminus.   
Very few studies have been carried out on Sar1 function and interaction 
when compared to Arf1, however there are some important differences between 
the two regulatory GTPases.  As previously mentioned, Sar1 controls the 
assembly of proteins coats (COPII) that bud proteins from the ER (see section 
1.8.1). Aridor et al (Aridor et al., 2001) found that activation of Sar1 alone leads 
to the formation of ER-derived tubular domains that resemble the ERGIC, 
highlighting its key importance in vesicle transport.  Sec12 is the only known 
GEF for Sar1 and it interacts with the protein through a motif of nine 
hydrophobic amino acids known as STAR (Sar1-NH2-terminal activation 
recruitment motif) (Huang et al., 2001).  The STAR motif along with the NH2-
terminal amphipathic helix (see section 1.8.1) facilitates pre-budding complex 
formation and cargo selection (Huang et al., 2001). Sec12 shares no apparent 
sequence identity with the Arf-GEFs and possesses a unique transmembrane 
spanning segment allowing its localisation to the ER membranes (Boehm et al., 
1997; Sato et al., 1999; Sato et al., 1996).  In contrast Arf1-GEFs are soluble 
and their localisation is thought to be through interactions with specific receptors 
(see section 1.8.2).  The GAP for Sar1 is the Sec23 (see section 1.8.1) which is 
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part of the COPII coat complex.  This Sec23 subunit stimulates Sar1 GTPase 
activity which is increased 10 fold by the addition of the Sec13/31 complex.  In 
contrast, Arf GTPase does not appear to be activated by a COPI subunit, 
instead the addition of Arf-GAP complexes creates GTPase activity (Goldberg, 
1999).  
Arf1 primarily co-localises to the Golgi complex in mammalian cells 
(Stearns et al., 1990) and induces the recruitment of COPI coat proteins to the 
Golgi membranes involved in transport (see above section 1.8.2).  All Arfs have 
a myristylated amino terminus that is required for membrane binding and 
function.  Arfs have been divided into three different classes based on amino 
acid sequence (Tsuchiya et al., 1991).  In total there are six mammalian Arf 
proteins: Arf1, Arf2 and Arf3 make up Class I; Arf4 and Arf5 comprise Class II; 
and Arf6 is the only member of Class III.  Class I Arfs function at the Golgi 
complex and it is thought they may have interchangeable functions.  Arf5 may 
also function at the Golgi (Claude et al., 1999; Kawamoto et al., 2002) whereas 
Arf6 is found localised to the plasma membrane (Al-Awar et al., 2000; Peters et 
al., 1995). 
Arf’s are converted into a GTP-bound state after recruitment to the 
membrane and activation by GEFs (see section 1.8.2).  There are four families 
of Arf-GEFs: the Gea/GBF1, Sec7/BIG1/BIG2, ARNO/cytohesin and EFA6 
(Jackson and Casanova, 2000).  The Gea/GBF1 and Sec7/BIG families localise 
to the Golgi and are usually inhibited by BfA (see section 1.6.4.1) whereas the 
remaining other two families, ARNO/cytohesin and EFA6, are BfA insensitive.  
In mammalian cells GBF1 is associated with the ERGIC and the Golgi (Garcia-
Mata and Sztul, 2003; Kawamoto et al., 2002; Zhao et al., 2002) whereas, 
Sec7/BIG localises to the trans-Golgi, trans-Golgi network (TGN) and recycling 
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endosomes (Mansour et al., 2002; Shin et al., 2004; Shinotsuka et al., 2002).  
GBF1 is known to interact with p115, a Golgi tethering protein (Garcia-Mata and 
Sztul, 2003), which maybe important for creating a scaffold to aid Arf1 
recruitment and activation at the Golgi membranes (Donaldson et al., 2005).  
GBF1 is also thought to be the GEF responsible for the activation of Arf1 on the 
Golgi to form COPI vesicles (see section 1.8.2). 
More than 16 Arf-GAPs have been identified in the human genome (Nie 
et al., 2003) which all contain a zinc-finger and catalytic domain. The Arf-GAP 
(Arf-GAP1) was the first to be identified (Cukierman et al., 1995) and is 
localised to the Golgi via an interaction with carboxyl terminal of the protein 
(Huber et al., 1998; Yu and Roth, 2002).  Over-expression of Arf-GAP1 
disassembles the Golgi, a phenotype very similar to BfA treatment or 
expression of a dominant negative Arf1 T31N (Dascher and Balch, 1994).  
Over-expression of other Arf-GAPs does not have this effect, therefore 
suggesting that Arf-GAP1 influences Arf1 activity in the early secretory pathway 
(see section 1.8.2). 
1.9 Rab proteins 
Rab proteins exist in all eukaryotic cells and form the largest group within 
the Ras super family (ras-related in brain) of GTPases, with over 70 different 
Rab proteins identified in the human genome (Bock et al., 2001).  Rab proteins 
are localised to the cytoplasmic surface of all organelles and regulate discrete 
transport steps along the secretory and endocytic pathways. Here they are 
involved in all stages of membrane trafficking including  budding, transport, 
tethering and fusion events. Rab1, 2 and 6 act at the ER and Golgi and are 
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involved in the secretory pathway (Gonzalez and Scheller, 1999; Martinez and 
Goud, 1998). 
  Rabs are soluble proteins present in the cytosol sequestered by Rab 
escort proteins (REPs) that chaperone the Rab protein around the cell.  Initially 
the REPS deliver the Rab protein to the geranylgeranyl transferase enzyme for 
prenylation where one or two hydrophobic geranylgeranyl groups are added to 
enable insertion into the cellular membrane (Anant et al., 1998). The Rabs are 
then delivered to the appropriate membrane where their lipid attachment allows 
them to insert into the bilayer (Alexandrov et al., 1994).   
Rabs go through an insertion-extraction cycle from the membrane.  Rabs, 
like other Ras-like proteins exist in GDP-bound inactive form in the cytosol. 
GDP dissociation inhibitor (GDI) binds to prenylated Rabs in their GDP bound 
form, maintaining Rabs in the cytosol (Ullrich et al., 1993). Therefore membrane 
attachment of Rabs, requires a GDI displacement factor (GDF) which 
dissociates both GDI and REPs from the Rab (Dirac-Svejstrup et al., 1997).  
Once GDI has been dissociated, the Rab specific GEFs can stimulate GTP-
binding and membrane binding through the Rab prenylated residues (Yang et 
al., 1998).  As with all Ras proteins the exchange of GDP for GTP is mediated 
by specific GEFs.  GEFs trigger the binding of GTP to the Rab resulting in it 
binding to the membrane and this in turn activates the protein.  Active Rabs are 
now able to bind to their specific effectors and carry out their roles in membrane 
trafficking.  GAP proteins hydrolyse GTP thereby releasing the Rab from the 
membrane where GDI sequesters the Rab in the cytosol.  Over 51 Rab specific 
GAPs have been identified to date all of which contain a conserved TBC (Tre-
2/Bub2/Cdcl6) domain (Bernards, 2003). 
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1.9.1 Effector proteins 
 Effectors proteins bind to specific Rab proteins to initiate one or more 
downstream effects (Munro, 2002; Pfeffer, 2001; Zerial and McBride, 2001).  
They bind specifically to Rabs in their GTP bound state (Harrison et al 2003). 
Rabs can signal through a variety of different effectors that act together to 
translate the signal from one Rab protein to multiple aspects of membrane 
transport (de Renzis et al., 2002; Segev, 2001).  Effectors create specific 
membrane domains and these domains can mature in the form of a Rab 
cascade mechanism, which allows the GEF of one Rab to serve as a effector 
for another Rab (Grosshans et al., 2006).  Effectors involved in membrane 
fusion are termed SNAREs (Brodsky et al., 2001; Jahn and Grubmuller, 2002; 
Sollner, 2004).  SNARE proteins interact to form stable complexes.  It is thought 
two SNARE proteins attached to different membranes may be able to form a 
“zipper”, driving fusion between the two membranes (Melia et al., 2002). 
1.9.2 Rab1 
 The Rab1 GTPase is present in two isoforms A and B, which have both 
been implicated in the regulation of anterograde transport of cargo between the 
ER and Golgi (Plutner et al., 1991; Tisdale et al., 1992).  Rab1 localises to the 
ERGIC membrane (Saraste et al., 1995)  and has been seen to associate with 
the ERGIC that accumulates in transport arrested cells absent of cargo proteins 
(Palokangas et al., 1998).  More recently, studies have now shown that Rab1 is 
the only single GTPase essential for anterograde transport through the Golgi 
and maintenance of the Golgi structure (Haas et al., 2007; Itoh et al., 2006).   
Rab1 regulation has been linked to the recruitment of COPI protein coats.  The 
dominant-negative mutant of Rab1 is able to block forward transport and disrupt 
the Golgi, causing Golgi proteins to relocate to the ER (Haas et al., 2007).  
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Inactive Rab1 also causes the redistribution of the ERGIC to a punctate 
structure.  It was also observed that while COPII exit machinery remained 
functional, COPI was compromised, as β-COP was released into the cytosol.  It 
can be concluded that Rab1 influences COPI recruitment and may play a role in 
Arf and its GEF (GBF) mediated COPI recruitment (Alvarez et al., 2003). 
 Rab1 activity is also involved in the regulation of vesicle tethering and 
docking on acceptor membranes.  Tethering factors consist of long coiled-coil 
proteins including p115, golgins and EEA1 (Allan et al., 2000).  Coiled-coil 
tethers are thought to act as bridge between the vesicle and target membrane.  
For example, vesicle associated protein p115 interacts with GM130 (a Golgi 
residing protein) and GRASP65, producing a complex that is thought to tether 
ER derived vesicles to the Golgi complex (Moyer et al., 2001; Plutner et al., 
1990; Tisdale et al., 1992).  The role of Rab1 maybe to regulate the assembly 
and/or activity of GM130/GRASP65 complex ensuring the specific activation of 
p115, and prevent its mis-targeting (Alvarez et al., 2001). 
1.9.3 Rab2 
 Rab2 has been shown to be essential for the maturation of the ERGIC.  It 
is resident of the ERGIC, and is required for protein transport from the ER to the 
Golgi complex (Tisdale et al., 1992).  Rab2 binds to the ERGIC to promote the 
recruitment of soluble components that aid membrane fusion and cytoskeletal 
interaction.  This results in the release of retrograde-directed transport vesicles 
(Tisdale, 1999; Tisdale and Jackson, 1998).  Dominant-negative GTP-binding 
mutants of Rab2 inhibit vesicular transport between the ER and Golgi complex. 
This suggests that along with Rab1, they are essential for regulating the 
secretory pathway by being involved in vesicle fusion between early 
compartments of the pathway (Tisdale et al., 1992).  In addition to regulation of 
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membrane flow from the ERGIC to the Golgi, Rab2 is also involved in the 
transport from the Golgi back to the ER (Tisdale, 1999; Tisdale et al., 1992; 
Tisdale and Jackson, 1998).  This is thought to be achieved by Rab2 recruiting 
PKCl/x to ERGIC membranes, which promotes the recruitment of COPI to 
generate retrograde transport vesicles. Therefore, Rab2 plays a critical role in 
maintaining the ERGIC in a steady state. (Tisdale, 1999, 2000; Tisdale and 
Jackson, 1998). 
1.9.4 Rab6 
 Rab6 is known to form a number of effector complexes mostly with motor 
proteins. This is required for microtubule transport between organelles.  The 
Rab6 protein is believed to directly link transport vesicles to the cytoskeleton.  
Rab6 is a Golgi associated protein, which is shown to interact with a kinesin-like 
protein, Rabkinesin-6 (Echard et al., 1998), and is connected to tubular 
structures moving along microtubules from the Golgi to the cell membrane.  
Rab6 could aid the transport of these structures to their acceptor organelles, 
most likely the ER.  In addition, Rab6 and Bicaudal-D have been seen to 
combine to tether transport vesicles destined for the Golgi to the cytoskeleton 
and once again collect them at the perinuclear region (Girod et al., 1999; 
Mallard et al., 2002; Young et al., 2005). 
1.9.5 Other Rabs involved in the early secretory pathway 
 Rab34 localises to the Golgi and is implicated in manoeuvring lysosomes 
to the cell centre (Wang and Hong, 2002) It is also believed to be involved in 
intra-Golgi transport with the early secretory pathway (Goldenberg et al., 2007).  
Rab8 is thought to form an effector complex with Rab8ip, involving it in trans-
Golgi to plasma membrane transport (Huber et al., 1993).  Similarly, Rab11 has 
been reported in the late recycling of transferrin receptors (Ren et al., 1998) 
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from the trans-Golgi network (TGN) to plasma membrane transport (Chen et al., 
1998).  This list of Rab proteins however is likely to be incomplete, and the 
involvement of other Rabs in the early secretory system remains to be 
determined. 
1.10 The early secretory pathway and viruses 
Many pathogens replicate in specialised compartments including bacteria 
and viruses.  All positive-strand RNA viruses, along with several DNA viruses 
(e.g. Vaccinia virus and African horse sickness virus) induce host cell 
membrane rearrangements required for the formation of replication complexes.  
The majority of these viruses have implicated membranes from the early 
secretory pathway in this process, with the ER playing a major role in vesicle 
formation.  The formation of membrane structures by viruses is believed to 
allow the accumulation of components required for replication.  This would not 
only provide a platform for the replication complex, but would also allow evasion 
of the immune response which would normally be triggered by the presence of 
dsRNA. 
1.10.1  Membrane rearrangements 
Several studies have shown that the individual expression of viral proteins 
causes membrane rearrangements similar to those observed in infected cells.  
Enterovirus non structural protein 2BC in conjunction with 3A induces formation 
of membrane vesicles with the same morphology as cells infected with the full 
length genome (Barco and Carrasco, 1995; Bienz et al., 1983; Cho et al., 1994; 
Suhy et al., 2000).  Similarly, Hepatitis C transmembrane protein NS4B was 
shown by EM to alter host cell membranes into a membranous web that is 
usually observed during infection and in cells expressing subgenomic replicon.  
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Flavivirus non-structural protein 4A  appeared to locate to RC’s in infected cells 
(Mackenzie et al., 1998; Miller et al., 2007), and when expressed alone induced 
membrane vesicle formation, which is thought to support vRNA replication 
(Miller et al., 2007; Roosendaal et al., 2006).  More recently Bailey et al found 
feline calicivirus proteins p32, p39 and p30 all localised to ER and possessed 
potential transmembrane domains.  Further investigation found that expression 
of these proteins lead to the reorganisation of the ER membranes, suggesting 
they play a role in replication complex formation (Bailey et al., 2010). 
1.10.2  Blocking of ER to Golgi transport 
In addition to individual viral proteins inducing host cell membrane 
rearrangements, several viral proteins have been identified as possessing the 
ability to block transport through the early secretory system.  Arresting transport 
in this way may possibly be a strategy to evade the immune response.   A 
consequence of the block of ER to Golgi transport could prevent the 
presentation of the major histocompatibility complex (MHCI) on the cell surface; 
the cell would not be marked for degradation, allowing infection to continue 
undetected.  The block in secretion by PV appears to be mediated by 3A which 
when expressed alone in cells is able to reduce the secretion of components of 
the immune response such as β-interferon, interleukin 6 and 8, this also results 
in the reduction of MHCI expression on the cells surface (Choe et al., 2005; 
Deitz et al., 2000; Dodd et al., 2001).  FMDV infection was also found to reduce 
MHCI cell surface expression (Sanz-Parra et al., 1998), however unlike PV, the 
co-expression of FMDV 2B and 2C viral proteins or the precursor 2BC is 
required to block secretion within the cell (Moffat et al., 2007).  Another 
enterovirus, Coxsackie B3 is believed to utilise a number of viral proteins to 
block secretion at the Golgi; it was observed that non structural proteins 2B, 2C 
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and 3A are all able to block secretion, with 3A showing the strongest block 
(Cornell et al., 2006).  
1.10.3 Host cell protein interactions 
To enable a block in protein secretion, disruption of the Golgi apparatus 
and host cell membrane rearrangements, viral proteins interact with many host 
cell proteins, many of which are linked to the early secretory pathway.  The 
prime example of this is the work done on PV.  COPII vesicle budding from the 
ER has been suggested to occur at the beginning of PV infection to form the 
replication vesicles (see section 1.6.4).  Formation of PV vesicles appeared 
morphologically similar to the formation of COPII vesicles, with Sec13/31, a 
component of COPII vesicles co-localised on PV vesicles surface.  The 
precursor 2BC or the entire P2 and P3 coding region appeared to be able to re-
produce vesicles containing a COPII coat.   This was observed early in infection 
and did not appear to involve the Golgi at this point (Rust et al., 2001).  
However, the observation that PV is sensitive to BfA treatment (Gazina et al., 
2002; Maynell et al., 1992), which only effects Arf1 GEFs and not effect COPII 
formation (Ward et al., 2001), lead to several studies producing evidence that 
Arf1 may be involved in PV RC formation.  Initially Belov et al (Belov et al., 
2005) observed that Arf1 translocated to PV replication complexes, and PV 3A 
and 3CD bound Arf to membranes due to the translocation of Arf GEF’s GBF1 
and BIG1/2 to membranes (Belov et al., 2008; Belov et al., 2005; Belov et al., 
2007b). The recruitment of Arf onto membranes would normally result in the 
formation of the COPI complex suggesting the recruitment of these proteins 
may result in the formation of RC complexes in PV infected cells.  However 
evidence shows that 3A alone does not result in vesicle formation and BfA 
treatment does not prevent the formation of vesicles in PV infected cells, 
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perhaps indicating Arf-GEF activity is not actually required for RC formation 
(Belov et al., 2008).  One explanation could be that RC’s could be formed early 
on in infection from COPII vesicles; 3A and 3CD may then divert the GEFs and 
Arf from the early secretory pathway to the already formed RC’s to aid 
replication (Belov and Ehrenfeld, 2007). In contradiction, Cherry et al produced 
a study indicating PV vesicle formation was only inhibited when COPI was 
depleted from cells, whereas loss of COPII had no effect on the vesicle 
structure (Cherry et al., 2006).    Interestingly PV 2C was found to be a GTPase 
(Rodriguez and Carrasco, 1993, 1995), and when a single point mutation was 
introduced to the protein it resulted in PV becoming resistant to BfA (Crotty et 
al., 2004). This may suggest a role for 2C in vesicle formation and/or 
stabilisation.   Coxsackie B3, another BfA sensitive virus also uses 3A to bind to 
Arf GEF GBF1, however 3A was found to inhibit Arf GEF activity and reduces 
Arf-GTP in the cells (Wessels et al., 2007; Wessels et al., 2006a; Wessels et 
al., 2006b).  The action of Coxsackie 3A is thought to block secretion by 
stabilising Arf1-GDP-GBF1 complexes therefore reducing the amount of Arf-
GTP for COPI formation.  Echovirus 11 infection has been shown to redistribute 
COPI to viral replication complexes; this virus is also sensitive to BfA (Gazina et 
al., 2002) which may indicate a direct role for COPI in virus replication. 
Parechovirus infection also resulted in COPI being observed in the replication 
vesicles.  In addition it was also dispersed through the cytoplasm (Gazina et al., 
2002) which showed a similar pattern observed in BfA treated cells. Currently, 
there is no evidence for the use of either COPI or COPII vesicles in BfA 
insensitive viruses such as EMCV and FMDV (Gazina et al., 2002).   
Hepatitis C virus NS4B creates a membranous web used for replication of 
vRNA (Gosert et al., 2003).  HCV was shown by a yeast-two hybrid system to 
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interact with the cellular GAP TBC1D20, this protein was also found to be 
required for efficient replication (Sklan et al., 2007b).    TBC1D20 regulates the 
early secretory pathway through its interaction with Rab1, which plays a role in 
regulating traffic between the ER and Golgi. Over-expression of TBC1D20 was 
found to block transport from the ER, whereas depletion of Rab1 reduced HCV 
RNA levels.  This suggests a role for Rab1 in HCV replication through an 
interaction with GAP TBC1D20 (Sklan et al., 2007a). 
Coronavirus nsp 3, 4 and 6 are thought to form replication complexes from 
the ER of infected cells (Knoops et al., 2008).  Coronavirus Mouse Hepatitis 
virus (MHV) is believed to rely on the early secretory pathway to form replication 
complexes, as when ER export machinery was blocked by either the kinase 
inhibitor H89 or by expression of the mutant Sar1 H79G, replication was 
inhibited (Oostra et al., 2007).  It was also noted by IF that replication sites 
themselves did not form, indicated by the lack of dsRNA present after infection 
in the presence of H89 (Oostra et al., 2007).  MHV was also found to be BfA 
sensitive as both the drug and expression of the dominant negative Arf1 T31N 
significantly reduced infection.  MHV replication was however not affected by 
BfA in MDCK cells.  MDCK are resistant to BfA treatment due to a mutation in 
the cells GBF1 preventing the drug from binding to the GEF.  Therefore, it was 
concluded that GBF1 activation of Arf1 was required for MHV replication 
(Verheije et al., 2008). In contrast, a study on SARS-coronavirus showed that 
although BfA treatment of infected cells reduced infection by around 80%, 
formation of the vesicles and viral replication were not blocked completely.  
Confocal microscopy also showed that components from the early secretory 
pathway did not localise with the SARS-CoV replication complexes.  This 
evidence allowed them to conclude that the early secretory pathway did not play 
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a direct role in replication of the virus and that the effects of BfA treatment on 
the cell, such as a loss of membrane integrity, may cause the loss of replication 
observed (Knoops et al., 2010). 
1.11 Aims
To date very little is known about how Foot-and-Mouth Disease Virus 
(FMDV) rearranges host cell membranes to form its replication complexes 
(RCs). This PhD thesis aims to gain a better understanding of how FMDV 
utilises regulatory proteins in the early secretory pathway to help form 
replication complexes that are believed to act as platforms for viral replication. 
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2 Chapter 2: Materials and Methods 
2.1 Cell Culture 
Baby Hamster Kidney cells, strain 13 (BHK-21) were purchased from the 
European Cell Culture Collection. The porcine kidney cell line IBRS-2 was 
provided by the central services unit (CSU) at the Institute for Animal Health 
(IAH). An alternative porcine kidney cell line, MAX, were a kind gift from Julian 
Seago at IAH.  HeLa cells were obtained from Imperial College, London. 
BHK-21 cells were maintained in Glasgow Minimum Essential Medium 
(GMEM) (Sigma) containing 10% foetal bovine serum (FBS) (Autogen Bioclear), 
2 mM glutamine (IAH), 100 U/ml penicillin (IAH), 100 μg/ml streptomycin (IAH) 
and 5% tryptose phosphate broth solution (Sigma). 
 IBRS-2 cells were cultured in GMEM containing 10% Adult Bovine Serum 
(ABS) (Gibco), 100 U/ml penicillin (IAH), and 100 μg/ml streptomycin (IAH).  
MAX cells were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) 
plus L-Glutamine, 25mM Hepes (Gibco) containing 10% FBS (Autogen 
Bioclear), 100 U/ml penicillin (IAH), 100 μg/ml streptomycin (IAH). 
HeLa cells were maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Sigma) containing 10% FBS (Autogen Bioclear), 100 U/ml penicillin 
(IAH) and 100 μg/ml streptomycin (IAH). 
All cells were grown at 37oC, 5% CO2 and routinely passaged three times 
a week.
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2.2 Virus 
Virus stocks were stored at -80°C.   Experiments utilise the non-heparin 
binding FMDV strain O1Kcad2, the heparin binding FMDV laboratory strain, 
O1BFS and Bovine Enterovirus type 1 (BEV-1). Working stocks were prepared 
using BHK-21 cells for FMDV and IBRS-2 cells for BEV-1.   
2.2.1 Preparation of virus working stocks 
Either BHK-21 (FMDV) or IBRS-2 (BEV-1) were grown in 175cm2 tissue 
culture flasks until confluent.  The cells were then washed with Phosphate 
Buffered Saline (PBS) and a 1ml aliquot of a previous virus stock was added to 
the cells.  This was incubated in a 37C incubator with 5% CO2 for 15 minutes 
before adding 20ml pre-warmed viral growth medium (VGM) consisting of 
normal growth medium with 1% serum.  The cells were returned to 37°C until 
cytopathic effect (CPE) was observed.  The cells were freeze thawed at -80oC.  
Working stocks of virus were centrifuged to remove cell debris and the 
supernatant aliquoted into 1.5ml screw capped eppendorf tubes and stored at   
-80C. 
2.2.2 Virus titration on coverslips 
Cells were plated onto 13mm coverslips (VWR International) in a 24 well 
tissue culture plate and incubated over night at 37oC until cells were 80-90% 
confluent.  Virus working stocks were diluted in a ten-fold serial dilution.  Cells 
were washed once in serum free media before adding 200μl of each dilution 
and incubating for 1 hour at 37oC.  After uptake, the virus was removed from the 
cells and replaced with VGM, before a further 3hrs at 37oC.  Coverslips were 
fixed in 4% paraformaldehyde (4% PFM) dissolved in PBS (Sigma), for 40 
minutes at room temperature, before being processed for confocal microscopy.   
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2.2.3 Virus titration by plaque assay 
Six well tissue culture plates of BHK cells were cultured overnight to 
reach approximately 80% confluency.  Virus working stocks were diluted with 
PBS in a ten-fold serial dilution; the cells were washed with PBS and 100μl of 
the appropriate dilution added to the cells.  The dishes were incubated at 37oC 
for 15 minutes before adding 3ml Eagle’s overlay (see appendix) at 45oC.  The 
overlay was allowed to set at room temperature and the cells returned to 37oC 
for the required time.  Plaques were visualised by fixing and staining with 
methylene blue and PFM in PBS for 12-24 hours. 
2.3 Antibodies and Reagents 
2.3.1 Primary Antibodies 
To detect FMDV infection by immunofluorescence, an antibody raised in 
rabbit against the FMDV-O capsid was used, (kindly donated by Nigel Ferris, 
IAH).  Anti-double stranded RNA antibody was obtained from English & 
Scientific Consulting Bt.  Bovine Enterovirus-1 (BEV-1) was detected through 
the use of a Guinea-pig anti-BEV-1 antibody (IAH).  Anti-c-myc 9E10 
(Developmental Studies Hybridoma Bank, University of Iowa) and high affinity 
anti- Haemagglutinin (HA) (Roche) enabled detection of plasmid expression.  
GM130 (BD Transduction Laboratories), 23C (a kind gift from Dr Harrison-
Lavoie), ERGIC-53 (Sigma) and Protein Disulphide Isomerase (PDI - Bioquote) 
labelled for the Golgi, Endoplasmic Reticulum-Golgi Intermediate Compartment 
(ERGIC) and Endoplasmic Reticulum (ER) respectively.   
Western blots were labelled with either anti-Sar1 (Millipore), anti-Rab5A 
(Santa-Cruz), or anti-Actin (Sigma) as a loading control.  
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2.3.2 Secondary Antibodies 
Species specific Alexa-Fluor conjugated secondary antibodies used for 
confocal microscopy were from Invitrogen (Molecular Probes).  Anti-
mouse/rabbit HRP secondary antibodies were used for western blot (Promega). 
2.3.3 Reagents
Pharmacological reagents were made up into stock concentrations and 
stored according to manufacturers guidelines. Brefeldin A (BfA) (10mg/ml) 
ready-made solution and Thapsigargin (1mg/ml in DMSO) were both from 
Sigma.  H89 Dihydrochloride (1mg/ml in DMSO) was from Calbiochem. 
2.3.3.1 Plasmids 
Plasmids for the expression of wild-type Cyan-fluorescent protein (CFP) 
Sar1a, the dominant negative CFP-Sar1a (T39N) and the dominant active CFP- 
Sar1a (H79G) was from A. Townley, University of Bristol. Plasmid expression of 
the wild-type Green-fluorescent protein (GFP) - Arf1 was donated by 
E.Ehrenfeld (NIAID, NIH, Bethesda, MD 20892, USA).  Dominant negative HA - 
Arf1 (T31N) and dominant active GFP- Arf1 (Q71L) and were both obtained 
from J. Lippincott-Schwartz (National Institutes for Health, Maryland, USA).  
Plasmid expression of wild-type myc–Rab1a, dominant negative myc-Rab1a 
(S25N), wild-type myc-Rab2, dominant negative myc-Rab2 (S20N), wild-type 
myc-Rab6 and dominant negative myc-Rab6 (T27N) were from T. Herbert 
(McGill University, Montreal, Canada).  Wild-type GFP-Rab34 and the dominant 
negative GFP-Rab34 (T66N) were obtained from N. Goldenberg (University of 
Toronto, Ontario, Canada).  The plasmids expressing GFP-TBC1D20 and the 
mutant version GFP-R105A were obtained from J.Glenn (University of Stanford, 
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California, USA). Finally, GFP-empty vector, GFP-Sec16L and GFP-Cterm-
Sec16L were from B.Glick (University of Chicago, Chicago, USA).     
2.3.3.2 siRNA 
siRNA targeting Sar1a and b (1a 005 sense:CUACAAGAAAUCCGGAAAAUU,  
anti-sense: UUUUCCGGAUUUCUUGUAGUU, 1a 007 sense: AGUCGAGCUUAAUGCUUUAUU, anti-
sense: UAA AGCAUUAAGCUCGACUUU, 1b 009 sense: CAUGAAAGGCUGUUAGAAUUU, anti-sense: 
AUUCUA ACAG CCU UUCAUGUU, 1b 013 sense: GCUCGGAGAGUGUGGAAAAUU, anti-sense: 
UUUUCCACACUCUCCGAGCUU ) were custom designed from  Dharmacon. Allstars 
non-target siRNA used as a negative control was from Qiagen.  SIGLO 
(Thermoscientific) allowed detection of transfection efficiencies. The Human 
Rab custom siRNA library from Ambion (see appendix III) was a generous gift 
from Ian Goodfellow at Imperial College, London. 
2.3.3.3 Primers 
Sar1a and b primers used to sequence Sar1 from IBRS-2 cells were from 
Sigma, (Sar1a forward: ATGTCCTTCATATTTGACTGG, Sar1a reverse: TCAGTCAATATACTGGGAGA GCCA 
GCGG AAGCCCTCG, Sar1b reverse: TTAATCTATGTACTGGGCCATCCAGCGGAAGCTTTCT). 
GAPDH and FMDV primers and probes (Sigma) used for quantitative PCR 
included: (GAPDH forward: GCATCGTGGAGGGACTYATGAC, GAPDH reverse: AGCCCCTCGGCCRTCA, 
GAPDH probe: [6FAM]CCATCACTGCCCACCCAGAAGACTGTG[TAM],  FMD 3D forward: ACTGGGTTTTACAAA 
CCTGTGA, FMD 3D reverse: GCGAGTCCTGCCACGGA, FMD 3D probe: [6FAM]CCTTTGCACG 
CCGTGGGAC[TAM]. 
The primers used to sequence p-GEM-T easy plasmid (Promega) with 
Sar1a and b inserts were the T7 promoter and SP6 promoter primers from 
Promega. 
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2.4 Virus Infectivity assays 
Infection was quantified using three methods: Immunofluorescence; 
titration of viral supernatant and Quantitative Polymerase Chain Reaction 
(QPCR). 
2.4.1 Immunofluorescence assay 
Cells were seeded on 13mm coverslips (VWR International) in 24 well 
tissue culture plates so as to reach 40-50% confluency overnight. Cells were 
transiently transfected (see section 2.5.10) with mammalian expression 
plasmids (see section 2.3.3.1), using Lipofectamine 2000 (Invitrogen). After 
incubation at 37C for 14 hours, cells were washed and infected with FMDV 
O1Kcad2 for a total of 3.5 hours at MOI = 0.5.  The same procedure was used 
for bovine enterovirus (BEV).  The cells were then fixed with 4% PFM for 40 
minutes at room temperature, and washed three times with PBS.  Coverslips 
were either processed for confocal microscopy or stored at 4oC under PBS. 
2.4.2 Infectivity assay 
For the collection of viral supernatants and QPCR samples, cells were 
seeded in a 24 well tissue culture plate overnight to reach around 40-50% 
confluency. Transient transfection of the cells (see section 2.6.1.) was 
performed using Lipofectamine 2000 (Invitrogen) with siRNA (see section 
2.3.3.2).  After incubation at 37oC for 48hrs, cells were washed with serum free 
media and virus was added at an MOI =0.5 for 40 minutes at 37oC. An acid 
wash (see appendix I) was added for 3 minutes at room temperature to remove 
any unbound virus.  The cells pH was neutralised with serum free media, before 
1ml VGM was added.  A time zero sample of either supernatant or lysed cells 
was collected in screw capped eppendorfs and stored at -80oC. The remaining 
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samples were incubated for a further 3 hrs at 37oC.  After incubation the 
remaining supernatants were collected in screw capped eppendorfs and stored 
at -80oC until titrated (see section 2.2.3).  The remaining cells were lysed in 
Qiagen AVL buffer for 10 minutes at room temperature and RNA extracted 
using a QiaAMP viral RNA mini kit (Qiagen). 
2.5 DNA Techniques 
2.5.1 Transformation of competent cells 
 Competent cells were thawed for 5 minutes on ice.  An aliquot of DNA 
was added to 50μl of competent cells and the mixture incubated on ice for 30 
minutes.  The samples were then heat shocked for 50 seconds at 42oC, and 
incubated for 2 minutes on ice.  1ml of LB was added and the culture incubated 
for 60 minutes at 37oC. The transformed bacteria were then plated onto LB/agar 
plates containing a suitable antibiotic (e.g. Ampicillin [100μg/ml]).   
2.5.2 Isolation of Plasmid DNA 
2.5.2.1 Small scale plasmid purification (mini-preps) 
Between 3-5ml of LB broth was inoculated with a single bacterial colony 
and incubated overnight at 37°C with continuous shaking at 200 rpm.  1.5ml of 
the culture was transferred to a fresh eppendorf tube and centrifuged at 
13,000rpm for 1 minute.  DNA was extracted using the Qiagen mini-prep 
system following manufacturer’s instructions.  DNA was analysed on a 1% 
agarose gel. 
2.5.2.2 Large scale plasmid purification (Maxi-preps) 
Around 50-100ml of LB media was inoculated with 50µl-1ml of starter 
culture and grown up overnight at 37oC, 200rpm.  DNA was extracted using the 
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Qiagen endo-toxin free maxi-prep system as per the manufacturer’s 
instructions, and DNA analysed after restriction digestion on a 1% agarose gel. 
2.5.3 Restriction digests 
Digests were carried out in a total volume of 20l according to 
manufacturer’s instructions supplied with each enzyme (Promega).  
2.5.4 DNA gel electrophoresis 
DNA was analysed by gel electrophoresis using 1-1.2 % agarose 
(Invitrogen) gels containing a final concentration of 0.5μg/ml ethidium bromide 
solution (Promega). Gels were run at a constant 100V. 
2.5.5 Nanodrop – Quantification of DNA concentration 
To determine DNA concentration, one microlitre (μl) of DNA was applied to 
the Nanodrop (1000) spectrophotometer on the DNA-50 setting to produce a 
reading in nanograms per μl. 
2.5.6 Polymerase chain reaction 
The polymerase chain reaction (PCR) was carried out with the use of a 
Taq DNA polymerase kit (Invitrogen). A master-mix was created (see table 
below) and added to 2μl cDNA in an RNase-free tube.  The Taq enzyme was 
added last (0.25μl/reaction). The reactions were run on a pre-programmed 
thermocycler (see appendix II). 
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Reagent Amount (per reaction) 
10X Buffer 5μl
50 mM MgCl2 1.5μl
10mM dNTPs 1μl
Forward primer (10pmol) 0.5μl
Reverse primer (10pmol) 0.5μl
Nuclease-free water 39.25μl
 
2.5.6.1 Quantitative PCR 
Quantitative PCR reactions were carried out as follows using the 
Taqman PCR Master-mix from Roche, forward and reverse primers and 6FAM-
TAM labelled probes (Sigma) (see section 2.3.3.3).  20μl of master-mix was 
added to 5 μl of cDNA, produced from prior reverse transcriptase reactions (see 
section 2.6.3), and loaded into a 96 well plate (Abgene). Reactions were run on 
a MX3005 quantitative PCR machine (Stratagene)(appendix II).  
Reagent Amount per reaction
Taqman master-mix 12.5μl 
Forward primer (10pmol) 2.25μl 
Reverse primer (10pmol) 2.25μl 
Probe (5pmol) 1.5μl 
Nuclease-free water 1.5μl 
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 2.5.7 DNA purification 
DNA was purified using the Wizard PCR purification kit (Promega) as per 
the manufacturer’s instructions. 
2.5.8 Ligations
Ligation Reactions were performed using p-GEM-T easy ligation kit 
(Promega) according to the manufacturer’s instructions. Ligations were 
performed using a vector : insert ratio of 3:1 in a total volume of 10μl.  Ligation 
mixes were incubated overnight at 4oC, and were subsequently transformed 
into JM109 cells. 
2.5.9 DNA sequencing 
DNA sequencing was carried out using a ABI sequencing kit (Applied 
Biosystems) as indicated below. 
Reagent Amount (per reaction)
10X Buffer 1.88μl
Reaction Mix 0.25μl
Primer 1μl at 10pmol
DNA template 250ng plasmid DNA 
Water To final volume 10μl 
 
The reaction was run on a thermocycler for the required length of time 
(see appendix II). The DNA was then ethanol precipitated, re-suspended in 40μl 
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of sample loading solution, and loaded on to the 96-well sequencing plate. The 
samples were run on a 48 capillary, 3730 DNA Analyzer (Applied Biosystems) 
and data analysed using Bioedit software.  
2.5.10 Transient transfection of mammalian cells with plasmid DNA 
Cells were seeded on sterile coverslips in transfection medium (cell 
culture medium without 100 U/ml penicillin and100 μg/ml streptomycin), aiming 
to be around 50% confluent the next day. 
Two master mixes were made; the first contained 1 μg plasmid DNA in 50 
μl opti-MEM (Invitrogen) per coverslip, and the second 1 μl Lipofectamine 2000 
(Invitrogen) in 50 μl opti-MEM per coverslip. Each master mix was incubated for 
5 minutes at room temperature. The two were then combined, mixed and 
incubated at room temperature for 20 minutes. 
Cells were washed once with 1 ml opti-MEM, and then 500 μl of fresh opti-
MEM was added to each coverslip. One hundred microlitres of the transfection 
complex was added drop-wise to the 500 μl opti-MEM, and the plate agitated to 
mix. Coverslips were incubated at 37oC, 5% CO2 for 4-6 hours, the opti-MEM 
was then removed and 1 ml transfection medium added. Each transfection was 
run for 12-14hrs. 
2.6 RNA Techniques 
2.6.1 siRNA transfection 
Cells were seeded on sterile coverslips in transfection medium so as to 
reach 40-50% confluency overnight. Transfection follows the method previously 
described in section 2.5.10, with the exception of the first master-mix which 
contained 10pmol of each siRNA in opt-MEM (Invitrogen) (see section2.3.3.2).  
All isoforms were targeted in one reaction, equalling between 30-40pmol in total 
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per coverslip. Both non-target siRNA (Qiagen) and SIGLO (Thermoscientific) 
were added at equivalent concentrations. 
Cells were washed once with 1 ml opti-MEM, then 400 μl fresh opti-MEM 
added to each coverslip. One hundred microlitres of the transfection complex 
was added to the opti-MEM. Coverslips were incubated at 37oC, 5% CO2 for 6 
hours, then the opti-MEM removed and 1 ml transfection medium added. All 
transfected cells were incubated for a total of 48 hrs. 
2.6.2 RNA isolation 
Total RNA was isolated from cell lysate using the Olido-dT bead kit 
(Invitrogen) following manufacturer’s instructions.  mRNA was separated from 
the oligo-dt beads by elution and denatured as protocol indicates, before 
proceeding onto reverse transcription reactions (RT) (see section 2.6.4). 
2.6.3 RNA extraction 
Cells were lysed in AVL buffer (Qiagen) at room temperature for 10 
minutes and RNA extracted using QiaAMP viral RNA mini kit (Qiagen) as per 
manufactures instructions. 
2.6.4 Reverse transcriptase reaction (RT) 
A master-mix of the RT reaction was made using the Taqman reverse 
transcriptase reagents (Roche) and nuclease-free water, to give each reaction a 
final volume of 30μl. One microlitre of RNA was added per reaction prior to 
running on a thermocycler (see appendix II). 
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Reagent Amount (per reaction)
10X Buffer 3μl
MgCl2 6.6μl
dNTP’s 6μl
Random Hexamers 1.5μl
RNasin 0.6μl
Reverse Transcriptase 0.75μl
 
 
2.7 Immunofluorescence
2.7.1 Setting up of coverslips 
Cells were plated onto borosilicate 13 mm coverslips (VWR International) 
in a 24 well plate, and incubated for a minimum of 16 hours at 37oC, 5% CO2, to 
be between 50-80% confluent the next day 
2.7.2 Detection of intracellular antigen following cell permeabilisation  
After transfection (see section 2.5.10 and 2.6.1) and/or infection (see 
section 2.4.1-2), coverslips were fixed with 4% PFM at room temperature for 40 
minutes, then washed three times with PBS. Coverslips were either labelled 
immediately or stored at 4oC under PBS. 
All subsequent steps were carried out at room temperature. Cells were 
permeablised with 0.1% Triton X-100 (Sigma) in PBS (Sigma) for 20 minutes. 
Cells were then washed twice with PBS and blocked with block buffer (Tris 
buffered saline, gelatin from cold water fish and goat serum) for 30 minutes to 
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prevent any unspecific binding. Cells were incubated with a primary antibody 
diluted in block buffer to detect the antigen of interest (200 μl per coverslip), for 
1 hour. Coverslips were then washed three times for 5 minutes with PBS before 
incubation with a species specific Alexa-Fluor labelled secondary conjugate 
antibody (Molecular Probes) in block buffer at 1/200 (200l per coverslip), for 1 
hour. Coverslips were washed as before and the nucleus stained with either 4’, 
6’-Diamidino-2-Phenylindole (DAPI) (Sigma) at 1:10,000 made fresh in H2O, for 
10 minutes at room temperature, or ToPro3 (Invitrogen) at 1:8000 dilution in 
PBS, for 5 minutes.  Each coverslip was then washed three times with PBS 
before being dipped in deionised H2O and the excess water blotted off. 
Coverslips were mounted in vectashield mounting medium for fluorescence 
(Vector Laboratories), on a glass slide (Agar Scientific), sealed with clear nail 
varnish, and stored at 4oC. 
2.7.3 Treatment of coverslips with pharmacological inhibitors prior to 
infection 
Cells were prepared on coverslips as in method 2.7.1. The following day 
cells were washed twice with serum-free medium, and pre-treated with 200 μl 
drug at pre-determined concentrations or mock-treated (including the solvent for 
the drug) for 30 minutes at 37oC, 5% CO2. Cells were then washed with serum-
free medium and virus (MOI = 0.5) added diluted in drug or solvent (for mock-
treatment) for 1 hour at 37oC, 5% CO2. Infection was continued in the presence 
of the drug as in method 2.4.1. 
2.8 Image Capture 
All coverslips were viewed on a Leica SP2 Confocal Scanning Laser 
Microscope and images were taken (n= ≥500 cells) using either the 63 x or 40 x 
lens. All data was collected sequentially to minimise cross-talk between 
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fluorescent antibodies. Images were processed using Adobe Photoshop 
software. 
2.9 Data Analysis 
Student’s t test was used to determine statistical significance (P values: * 
<0.05, ** <0.01, *** <0.001), n= >500 cells. 
2.10 Transmission Electronmicroscopy (TEM) 
Cells were seeded on Thermanox coverslips (VWR International) in 24 
well plates so cells would reach 50-80% confluency overnight. Coverslips were 
infected with FMDV-O for 3.5 hours in total (see section 2.4.1) before the 
addition of EM fixative (see appendix I) to chemically fix the samples. 
Samples were left in EM fixative for 90 minutes on a rotator at room 
temperature then fixed in 1% osmium tetroxide (Agar Scientific) for 60 minutes 
at room temperature. The cells were then dehydrated in an ethanol series: 
70% ethanol 30 minutes
90% ethanol 15 minutes
100% ethanol 3x10 minutes
 
Coverslips were transferred to polythene cups (TAAB, UK) and wash in 
propylene oxide (Agar Scientific) for 10 minutes prior to the addition of a 1:1 mix 
of propylene oxide and epoxy resin (Agar Scientific, made up as manufacturer’s 
instructions indicate) for 60 minutes on a rotatory mixer at room temperature.  
The above mix was replaced with 100% resin and incubated for 60 minutes at 
room temperature. 
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Coverslips were then transferred into fresh polythene cups with fresh resin 
ensuring the cells were facing upwards, and allowed to polymerise overnight at 
60oC.  Approximately 20 hours later, the Thermanox coverslips were peeled 
from the blocks.  Sections (70nm) of the resin blocks were collected onto 
copper grids and stained with uranyl acetate and lead citrate in a Leica EM 
AC20 staining machine.  Images were taken using the Phillips Technai 12 TEM 
with TVIPS F214 2Kx2K digital camera. 
2.11 Western Blot 
Samples were prepared by washing cells in PBS before lysing with Cellytic 
M cell lysis reagent (Sigma) for 2 minutes at room temperature.  Lysates were 
collected in 1.5ml eppendorfs and spun at 13,000 rpm for 5 minutes at room 
temperature to remove cellular debris.  The supernatant was either diluted in 
PBS (1 in 30) for protein quantification or added to reducing lane marker sample 
buffer (5X) (Thermoscientific) for western blot.  Western blot samples were 
heated to 90oC for 5 minutes and allowed to cool to room temperature. 
A micro Bioinchroninic (BCA) assay (Thermoscientific-Pierce) was carried 
out as per manufacturer’s instructions on the PBS diluted samples, to quantify 
the concentration of protein per sample, allowing the equal loading of protein 
onto the SDS-PAGE gels. 
Samples were run on an 10% acrylamide resolving gel (including 1.5 M 
Tris pH 8.8) and a 2.5% acrylamide stacking gel (including 1 m Tris pH 6.8) 
(see appendix I ). Samples were loaded onto the gel using a Hamilton syringe, 
and run at 100-200 V.  The proteins were transferred onto Hybond-C extra 
membrane (Amersham) at 100 V for 1.5 hour. 
89
The membrane was incubated in block buffer (5% semi-skimmed milk 
(marvel) in 1x PBS-Tween), with continuous rotation overnight at 4oC. Labelling 
was carried out at room temperature. The membrane was then incubated with 
primary antibody in block buffer for 1 hour and then washed in 1 x PBS-Tween 
for 1 hour, changing the wash every 15 minutes. The membrane was then 
incubated with the appropriate secondary HRP-conjugated antibody in block 
buffer for 1 hour and then washed as above. The membrane was finally 
incubated in ECL reagents (Pierce), made up as per manufacturer’s 
instructions, for 5 minutes. The bands were visualised on Kodak film developed 
manually using Polycon Manual X-ray Developer (Champion Photochemistry) 
and B&W Amfix, Film and Paper Fixer (Champion Photochemistry). 
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3 Chapter 3: Investigating the Early Secretory Pathway in 
FMDV Infection 
3.1 Introduction
  Picornaviruses induce host cell membrane rearrangements to facilitate 
their replication. These membranes are believed to act as platforms for 
formation of viral replication complexes (RC).  Membranes of the early secretory 
pathway have been implicated in the formation of RC’s by several 
picornaviruses. Early studies with poliovirus (PV) have implicated the ER (Rust 
et al., 2001) as the source of membranes for RC formation whereas more 
recent studies have identified a role for proteins associated with the Golgi 
membranes (Belov et al., 2005; Belov et al., 2007b; Cho et al., 1994; Hsu et al., 
2010) (see section 1.6.4).   
For both poliovirus and coxsackie B3 the 3A protein has been shown to 
block protein transport through the secretory pathway.  In contrast, for FMDV 
2BC and not 3A was shown to block protein transport (Moffat et al., 2005).  This 
block may indicate a role for 2BC and the early secretory pathway in FMDV 
replication and formation of RCs.  However, the interaction of FMDV 2BC with 
host cellular factors within the early secretory pathway has yet to be 
established. 
The IBRS-2 kidney cell line derived from the natural porcine host of FMDV 
was used to investigate the role of the early secretory pathway in FMDV 
replication.  
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3.2 Membrane rearrangements in FMDV infected cells 
Membrane rearrangements have been observed in BHK21 cells infected 
with FMDV (Monaghan et al., 2004) (see section 1.6.4).  To determine if host 
cell membrane rearrangements also occur in IBRS-2 cells, infected and 
uninfected cells were compared by TEM.  Cells were infected with FMDV 
O1Kcad2 (MOI 0.8) for 3.5 hours.  Infected and uninfected cells were then 
processed for TEM (see methods, 2.9). Figure 3.1 shows uninfected (panels A-
B) or infected cells (panels C-D).  Uninfected cells show a normal complement 
of organelles in the cytosol (Fig 3.1, A-B), whereas infection with FMDV resulted 
in the formation of membrane vesicles (Fig 3.1, C-D).  In infected cells remnants 
of the ER and a large number of membranous vesicles are present in the 
cytosol. The majority of these vesicles appear to possess a single membrane 
(Fig 3.1, panel C-D) although on occasion double membrane vesicles are seen. 
These results are similar to those seen previously for BHK cells and confirm 
that extensive membrane rearrangements are induced by FMDV infection of 
IBRS-2 cells.  
3.3 The effect of FMDV infection on membranes in the early secretory 
pathway 
 Next I investigated the effects of FMDV infection on the membranes in the 
early secretory pathway.  IBRS-2 cells were mock-infected or infected with 
FMDV O1Kcad2 (MOI 0.5) for 3.5 hours. The cells were then fixed with 4% pfm 
and permeablised using 0.1% Triton-X and then blocked for 1 hour in blocking 
buffer (see methods 2.7). The cells were then labelled for either the ER, the 
ERGIC or the Golgi using mouse antibodies to PDI, ERGIC53 or GM130 
respectively and a goat anti-mouse Alexa-488 conjugated secondary antibody.  
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The cells were co-labelled for FMDV infection using a rabbit polyclonal antibody 
to type O virus and a goat anti-rabbit Alexa-568 conjugated secondary antibody.   
Figure 3.2 shows labelling for mock-infected cells. Panel A shows a 
normal labelling pattern characteristic of the ER. Panel B shows labelling for the 
ERGIC; labelling was dispersed throughout the cytosol but most cells also 
showed a peri-nuclear area where labelling appeared more concentrated. Panel 
C shows a typical labelling pattern expected for the Golgi which is normally 
located in a peri-nuclear region.  
Figure 3.3 shows cells infected with FMDV (shown in red, panels B and D) 
and labelled for the ER (PDI shown in green).  The ER labelling was greatly 
reduced in infected cells and some cells showed localised areas of labelling in 
the cytosol.  Figure 3.4 shows cells infected with FMDV (shown in red, panels B 
and D) and labelled for the ERGIC (shown in green).  ERGIC labelling is greatly 
reduced in cells that appear at an advanced stage of infection (as judged by the 
intense labelling for FMDV) (Fig 3.4, panels A-B) while in cells that appeared to 
be at an early stage of infection the ERGIC was still present but fragmented and  
concentrated into large puncta (Fig 3.4 panels C-D).  Figure 3.5 shows cells 
infected with FMDV (shown in red, panels B and D) and labelled for the Golgi 
(GM130, shown in green).  The Golgi is clearly dispersed throughout the 
cytoplasm in cells infected with FMDV.  These results show that FMDV infection 
results in major disruption of membranes of the secretory pathway. 
3.4 The effect of Brefeldin A on membranes in the early secretory 
pathway 
Brefeldin A (BfA) is a fungal metabolite that blocks protein transport 
through the secretory pathway and causes a redistribution of Golgi proteins  
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back to the ER (Doms et al., 1989; Lippincott-Schwartz et al., 1990; Lippincott-
Schwartz et al., 1989) (see section 1.6.4.1). Brefeldin-A inhibits nucleotide 
exchange by  Arf1 (Donaldson et al., 1992; Helms and Rothman, 1992) by 
trapping the Sec7 domain of GBF1 in a non-productive complex with GDP and 
therefore preventing Arf activation (Mossessova et al., 2003; Renault et al., 
2003) and the recruitment of COPI components onto target membranes 
(Klausner et al., 1992; Orci et al., 1991). Hence BfA inhibits both protein 
secretion and PV replication.  In contrast FMDV is insensitive to BfA. Some 
cells (e.g. Madin-Darby Canine Kidney cells) carry mutations in the Sec7 
domain of GBF1 which results in a resistance to BfA (Niu et al., 2005). 
Therefore I characterised the effects of BfA on the membranes in the early 
secretory pathway in IBRS-2 cells.  
Cells were treated with DMSO (mock treated cells) or BfA (5g/ml) for 30 
minutes prior to being fixed in 4% pfm and processed for immunofluorescence 
confocal microscopy (IFCM).  Cells were labelled for the ER (using an antibody 
to PDI), the ERGIC (using an antibody to ERGIC53) or the Golgi (using an 
antibody to GM130) as described above.  Figure 3.6 shows labelling for mock 
and BfA treated cells.  Characteristic labelling was seen in mock treated cells 
for the ER (Fig 3.6, panel A) the ERGIC (Fig 3.6, panel C) and the Golgi (Fig 
3.6, panel E).  Figure 3.6 also shows the effect of BfA on membrane labelling.  
In comparison to the mock treated cells, BfA appears to cause a concentration 
of ER labelling (red) around the peri-nuclear region (blue) (Fig 3.6 shown as 
red, panel B), although this effect was not strongly observed in all cells. 
Labelling for the Golgi was greatly reduced and dispersed by BfA (Fig 3.6, 
panels F). Changes in the ERGIC were less dramatic than those in the Golgi;  
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however, the ERGIC labelling in the peri-nuclear region was dispersed in 
virtually all cells (Fig 3.6, panel D).  
3.5 The effects of Brefeldin A on FMDV infection
The above results confirm that BfA disrupts membranes of the secretory 
pathway in IBRS-2 cells. Previous published experiments have shown that 
FMDV infection is insensitive to BfA as virus yield is not reduced by exposure of 
cells to this reagent (Monaghan et al., 2004; O'Donnell et al., 2005). Next I 
confirmed the insensitivity of FMDV to BfA using IBRS-2 cells and BEV as a 
control virus that is known to be BfA sensitive (Monaghan et al., 2004).   
IBRS-2 cells were mock treated with DMSO or incubated with BfA (5g/ml) 
for 30 minutes prior to infection with either FMDV O1Kcad2 or BEV-1 (MOI 0.5) 
for 3.5 hours.  The cells were incubated with BfA (or DMSO) for the duration of 
the experiment.  The cells were fixed in 4% pfm, permeabilised with 0.1% 
Triton-X and blocked in goat serum prior to labelling with anti-FMDV or anti-
BEV-1 antibodies and the appropriate Alexa Fluor-conjugated secondary 
antibody and processed for IFCM.   
Figure 3.7 shows cells treated with DMSO (panels A and C) or BfA (panels 
B and D) and infected with FMDV (infected cells are shown in red on panels A-
B) or BEV-1 (infected cells are shown in red on panels C-D).  Brefeldin A 
treatment does not appear to have an effect on FMDV infection (A-B).  In 
contrast, BEV-1 labelling was not seen in BfA treated cells indicating that 
infection was inhibited.  The above experiments confirm that FMDV infection of 
IBRS-2 cells is insensitive to BfA treatment.   
The proportion of mock- or BfA-treated cells that were infected was determined. 
Approximately ~50% of DMSO treated cells and ~60% of BfA treated cells were  
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Figure 3.8 The effect of Brefeldin A treatment on FMDV infection
IBRS-2 cells were treated with DMSO or Brefeldin A (5ug/ml) for 30 minutes prior to 
infection with FMDV for 3.5 hours.  The proportion of cells infected is shown as the 
mean +/- SD of triplicate samples.
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Figure 3.9 Brefeldin A treatment blocks BEV-1 infection in IBRS-2 cells
IBRS-2 cells were treated with DMSO or Brefeldin A (5ug/ml) for 30 minutes 
prior to infection with BEV for 3.5 hours. The proportion of cells infected is 
shown as the mean +/- SD of triplicate samples.
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infected with FMDV (Fig 3.8) while for BEV, ~50% of mock treated cells were 
infected whereas infection of the BfA treated cells was completely inhibited (Fig 
3.9). These results confirm that FMDV infection of IBRS-2 cells is insensitive to 
BfA.   
3.6 Protein Kinase Inhibitor H89
The above experiments show that FMDV infection is not inhibited by BfA 
and therefore unlikely to require Golgi membranes for replication. Therefore it is 
possible that FMDV replication may require membranes derived from an earlier 
stage of the secretory pathway (e.g. the ER or ERGIC).   
 The isoquinolinesulfonamide H89 is a protein kinase inhibitor and when 
used in the micro molar range it blocks ER exit without affecting retrograde 
transport from the ERGIC or Golgi to the ER.   The block to ER exit is believed 
to results from a failure of SEC13 to be recruited to ERES (Lee and Linstedt, 
2000).   
3.6.1 H89 Blocks FMDV Infection 
To determine if FMDV replication was inhibited by a block to ER export, 
cells were treated with H89 (50 or 100m) or mock treated with DMSO for 30 
minutes prior to infection with either FMDV O1Kcad2 or BEV-1 (MOI 0.5) for 3.5 
hours.  The cells were incubated with H89 for the duration of the experiment.  
Cells were fixed in 4% pfm and labelled with either anti-FMDV or anti-BEV-1 
antibodies (as described above).  Figure 3.10 shows cells treated with DMSO 
(panels A and D) or H89 (100m panels B and E or 50m panel C) and infected 
with FMDV (shown in red, A-C) or BEV-1 (shown in red, D-E).  Infection of both 
FMDV and BEV-1 was completely inhibited by treatment with 100m H89   
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Fig 3.10 B and E). A reduction in FMDV infection was also observed in cells 
treated with 50m H89 (Fig 3.10 C). The proportion of H89 or mock treated cells 
that were infected with FMDV or BEV was determined and is shown in figure 
3.11.   Approximately 50% of mock treated cells (DMSO) were infected with 
FMDV, whereas H89 treatment dramatically inhibited infection (Fig 3.11, panel 
A-B).    Figure 3.12 shows that H89 (100m) also inhibited BEV infection.  The 
block of FMDV and BEV-1 infection by H89 suggests that both viruses rely on 
the early secretory pathway for replication. 
3.7 Endoplasmic Reticulum (ER) Stress 
The previous experiment suggested FMDV requires the early secretory 
pathway for replication.  An imbalance in protein homeostasis in the ER 
activates the Unfolded Protein Response (UPR) (also known as the ER Stress 
Response [ERSR]) (Patil and Walter, 2001; Schroder and Kaufman, 2005a, b).  
It has been reported that induction of ER stress results in a reduction in ER 
export and therefore COPII vesicle formation (Amodio et al., 2009).  To 
determine if FMDV infection is effected by ER stress, I investigated the effect of 
Thapsigargin (TG) on FMDV infection. Thapsigargin is a specific inhibitor of 
endoplasmic Ca (2+)-adenosine 5'-triphosphatase (Ca (2+)-ATPase) and 
induces ER stress. 
3.7.1 The effect of ER stress on membranes in the early secretory 
pathway 
Initially I investigated the effects of ER stress on membranes in the early 
secretory pathway using confocal microscopy.  TG (300nM) was used to induce 
ER stress in IBRS-2 cells.  Cells were incubated with TG for 4 hours, fixed in 
4% pfm and processed for IFCM. Figure 3.13 shows the effects of ER stress on 
the ER (labelling for PDI, panel B) the ERGIC (labelling for ERGIC53, panel D) 
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Figure 3.11 FMDV infection is inhibited by H89
IBRS-2 cells were treated with DMSO and 50 or 100m H89 for 30 minutes prior to 
infection with FMDV for 3.5 hours. The proportion of cells infected is shown. Panel 
(A) shows the effect of 50m H89 on FMDV infection.  Panel (B) shows the effect 
of 100m H89 on FMDV infection.
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Figure 3.12 BEV-1 infection is blocked by H89 treatment
IBRS-2 cells were treated with DMSO or H89 (100m) for 30 minutes prior to 
infection with BEV-1 for 3.5 hours. The proportion of cells infected is shown.
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and the Golgi (labelling for GM130, panel F) in comparison to mock treated cells 
(DMSO, panels A, C and E).  The labelling for the ER in TG treated cells 
appears to become condensed around the nucleus in comparison to mock 
treated cells although this effect was marginal in some cells (Fig 3.13, panels A-
B).  The ERGIC labelling appears to be dispersed or completely absent (Fig 
3.13, panels C-D).  In contrast, the Golgi labelling was still detected, however 
the Golgi did appear fragmented (Fig 3.13, panels E-F). These observations 
suggest that ER stress is causing an accumulation of protein at the ER due to 
reduced ER export and this in turn is preventing the formation of the ERGIC. 
However, these results suggest that TG may have an effect on the Golgi which 
prevents complete disruption of this organelle.   
3.7.2 ER stress does not block FMDV infection 
Next TG treated cells were infected with FMDV to establish if ER stress 
would have any effect on FMDV infection.   Cells were treated with TG as 
described above (section 3.7.1) and infected with FMDV O1Kcad2 for 3.5 hours. 
The cells were fixed in 4% pfm and processed for IFCM using the anti-FMDV 
antibody as described above. Figure 3.14 shows mock treated cells (panel A) or 
TG treated cells (panel B) infected with FMDV. The proportion of mock- or TG-
treated cells that were infected was determined. Approximately ~50% of DMSO 
treated cells and ~60% of TG treated cells were infected with FMDV (Fig 3.15). 
These results suggest that ER Stress does not block FMDV infection (see 
discussion, section 3.8). 
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Figure 3.15 ER stress does not inhibit FMDV infection in IBRS-2 cells
IBRS-2 cells were pre-treated with DMSO or Thapsigargin (TG) (300nM) for 4 hrs 
before infection with FMDV for 3.5 hrs. The proportion of cells infected is shown as 
the mean +/- SD of triplicate samples. 
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3.8 Discussion 
In this chapter I have examined the feasibility of using IBRS-2 cells to 
investigate FMDV induced membrane rearrangements using drugs that inhibit 
the secretory pathway and immunofluorescent confocal microscopy and 
Transmission Electron Microscopy (TEM). 
All positive strand RNA viruses are known to induce host cell membrane 
rearrangements.  Figure 3.1 shows evidence of membrane rearrangements and 
the formation of large membrane vesicles in FMDV infected IBRS-2 cells. The 
clearing of the cytoplasm and re-distribution of the cells cytoplasmic contents to 
one side of the nucleus was similar but not as extensive as seen in BHK21 cells 
(Monaghan et al., 2004).  These differences indicate that subtle differences in 
membrane rearrangements may occur in different cell lines. 
The data in figure 3.3 shows that FMDV infection results in a major 
disruption of membranes in the early secretory pathway.  The observed 
disruption to membranes in the early secretory pathway may be due to the 
action of the precursor 2BC which is reported to block protein secretion (Moffat 
et al., 2005; Moffat et al., 2007).  From these experiments it is not clear if FMDV 
has a direct effect on the ERGIC and Golgi or if disruption of the ER results in a 
reduced flow of membranes from the ER to the ERGIC/Golgi, hence the 
disruption of these membrane compartments. 
Brefeldin A inhibits protein transport by preventing the activation of Arf1.  
Brefeldin A treatment caused a loss of labelling for the Golgi marker GM130 
and the slight concentration of labelling for ER proteins.  These observations 
agree with published data that shows that BfA causes disruption of the Golgi 
and the re-absorption of protein back into the ER (Sciaky et al., 1997).  
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Brefeldin A is not thought to stop ER export and therefore does not collapse the 
ERGIC (Lippincott-Schwartz et al., 1990); however our data saw a slight loss to 
the peri-nuclear region of the ERGIC labelling. This difference may be due to 
the loss of the cis-Golgi that is thought to be continuous with the ERGIC and 
labelled with ERGIC53. However, the data appears to agree with another study 
that saw the redistribution of the ERGIC and Golgi to peripheral structures 
(Amodio 2009).   
The results of the experiment shown in figure 3.7 confirm that BfA blocks 
BEV-1 but not FMDV infection and that IBRS-2 cells are susceptible to BfA 
treatment.  Quantification of these results shows a complete loss to BEV 
infection, whereas a 10% increase to FMDV infection was observed. The 
increase in FMDV infection may suggest that BfA is enhancing FMDV 
replication; however such a small increase is not conclusive evidence.   
The protein kinase inhibitor H89 (100M) blocks FMDV and BEV infection 
completely when added immediately after virus entry, which suggests that H89 
is blocking replication. When used at 50M, H89 treatment is reported to cause 
a slow redistribution of Golgi proteins back to the ER (GM130 ~2hr) supporting 
that anterograde, but not retrograde transport is blocked. As FMDV replication 
does not require an intact Golgi, this suggests that FMDV may require 
membranes of the secretory pathway before the Golgi complex. The block to 
BEV infection may be due to the fact that anterograde transport is required for 
infection or that H89 treatment is in fact interfering with retrograde transport at 
the Golgi. 
Endoplasmic reticulum stress did not block infection; in fact around a 10% 
increase was observed. The observation that ER stress did not have any 
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detrimental effect on FMDV infection could be due to an incomplete block to 
COPII transport as Amodio et al (Amodio et al., 2009) showed only a 50% 
reduction in ER export in cells treated with Thapsigargin (300nM).  
In summary, FMDV infection appears to disrupt membranes in the early 
secretory pathway and cause the formation of large membrane vesicles.  In 
addition, infection is inhibited by a block to ER export by H89 but not by BfA 
which affects retrograde transport.  Overall, it appears FMDV requires the early 
secretory pathway before the BfA sensitive step and does not appear to require 
an intact Golgi. 
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4 Chapter 4: Investigating the Role of Sar1 in FMDV Infection 
4.1 Introduction
The experiments of the previous chapter confirmed the insensitivity of 
FMDV to BfA and suggested that FMDV infection requires the early secretory 
pathway. The sensitivity of PV to BfA results from its inhibitory effect on GBF1, 
the GEF of Arf1 (Donaldson et al., 1992; Helms and Rothman, 1992) (see 
section 1.6.4.1). One of the major differences between FMDV and PV is that 
FMDV is insensitive to BfA (Gazina et al., 2002; Martin-Acebes et al., 2008; 
Monaghan et al., 2004; O'Donnell et al., 2001).  Therefore, it can be assumed 
that FMDV does not require GBF1 or Arf1 for replication, and that FMDV is 
likely to be utilising other components of the early secretory pathway (before a 
BfA sensitive step) during infection.  COPII formation is mediated by Sar1 and 
its GEF, Sec12; it occurs before a GBF1/Arf1 mediated step and is unaffected 
by BfA treatment (Lippincott-Schwartz, 2001; Orci et al., 1993; Ward et al., 
2001). In this chapter a role for Sar1 in FMDV infection is investigated.  
Sar1 is bound to GDP in the cytosol and converted to a GTP-bound (or 
active) form by its GEF, Sec12.  Conversion to a GTP-bound form results in an 
insertion of Sar1 into the ER membrane and the recruitment of the COPII 
complex proteins that are required to form COPII transport vesicles.  Sar1-GTP 
is then hydrolysed by its GAP and disassociates from the membrane which 
promotes disassembly of COPII coats (see section 1.8.1).  
The involvement of Sar1 in FMDV infection was investigated using 
dominant-negative (dn) mutants of the protein, Sar1a T39N-CFP and Sar1a 
H79G-CFP.  Dominant-negative Sar1a T39N-CFP is GTP-restricted and 
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remains bound to GDP, which prevents Sar1 from interacting with its GEF, 
Sec12 (Kuge et al., 1994) and hence, Sar1 activation.  The dn activity of Sar1 
T39N results from a block to COPII vesicle formation and budding, and leads to 
the retention of transport proteins in the ER, ultimately blocking anterograde 
transport (Aridor et al., 1995).  Dominant-negative Sar1a H79G-CFP remains 
constitutively active (GTP-bound) and stabilises COPII coats (Dascher and 
Balch, 1994; Kuge et al., 1994; Oka and Nakano, 1994; Tanigawa et al., 1993).  
It does not interfere with coat assembly, or COPII vesicle formation or budding, 
however, COPII coat stabilisation prevents the disassociation of COPII and the 
subsequent acquisition of COPI (i.e. COPII/COPI exchange). In cells expressing 
dn Sar1a H79G, COPII vesicles appear to accumulate close to the ER in 
structures that resemble VTCs (Aridor et al., 1995; Ward et al., 2001). Although 
dn Sar1a H79G-CFP is locked in its GTP-bound form and therefore 
constitutively active, the fact that Sar1 cannot be released from the COPII 
complex results in an arrested transport at the ERES (Altan-Bonnet et al., 
2004).  Therefore Sar1a H79G-CFP is considered to be a dn protein.  
4.2 Investigating the role of Sar1 on FMDV infection using Dominant-
negative proteins 
4.2.1 The effects of dominant-negative Sar1a on membranes in the early 
secretory pathway 
Initially, the effect of dn Sar1 on membranes of the early secretory 
pathway was investigated by immunofluorescence confocal microscopy (see 
methods 2.7) using IBRS-2 cells.  IBRS-2 cells were transfected to express 
either wt Sar1a, dn Sar1a T39N or dn Sar1a H79G as fusions with CFP (which 
allows for detection of transfected cells) for 14 hours.  The cells were fixed with 
PFM and permeabilised with 0.1% Triton-X. They were then blocked in goat 
118
serum prior to labelling with antibodies to the ER (PDI), the ERGIC (ERGIC-53) 
or the Golgi (GM130 and 23C) and the appropriate Alexa-Fluor labelled 
secondary antibody.  Cells expressing a transgene (i.e. a Sar1 protein) are 
shown as Cyan on the figures.   
Untransfected cells were similarly labelled for the ER, ERGIC and the 
Golgi (shown in red).  Figure 4.1 shows the typical labelling patterns for these 
compartments.   As expected, labelling for the ER was seen throughout the 
cytoplasm (Fig 4.1, panel A) and labelling for the Golgi was confined to a peri-
nuclear region (Fig 4.1, panel B). Labelling for the ERGIC was also 
predominantly located to the peri-nuclear region but also showed some puncta 
dispersed through the cytosol (Fig 4.1, panel C).    
Figure 4.2 shows cells expressing wt Sar1a-CFP (shown as cyan in panels 
B and D) and labelled for the ER (shown as red on panels A-B) or the ERGIC 
(shown as red on panels C-D).  A slight reduction in ER labelling was observed 
in cells expressing the wt Sar1a-CFP (Fig 4.2 A-B).  However the ERGIC 
showed no obvious loss of labelling or integrity (Fig 4.2 C-D).  Figure 4.3 shows 
cells expressing wt Sar1-CFP (shown as cyan, panels B and D) labelled for the 
Golgi with either GM130 (shown as red, panels A-B) or 23C (shown as red, 
panels C-D).  Transfection of wt Sar1a-CFP caused no noticeable effect to 
either of the Golgi proteins.  In general, the expression of wt Sar1-CFP did not 
appear to have any major effect on the membranes of the ERGIC and Golgi but 
did cause a slight loss to ER labelling.  The loss of ER labelling may result from 
a dn effect of over-expression of wt Sar1.  However, overall, it appears that wt 
Sar1a-CFP does not alter the ERGIC or Golgi membranes and therefore is 
unlikely to have a major inhibitory effect on the secretory pathway. 
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